Gene editing in chickens : knockdown of Interleukin-6 using CRISPR by Liu, Qi
 
 
 
 
Gene Editing in Chickens: 
Knockout of Interleukin-6 using CRISPR 
 
 
 
 
By 
 
Qi Liu 
M. Agri. 
 
 
 
 
Submitted in fulfilment of the requirements for the degree of 
Doctor of Philosophy 
 
 
Deakin University 
August 2017
		

									
	
	
 
	
	

		
 
 
		
	
III	
Acknowledgements 
 
My PhD has been a long journey filled with numerous challenges. I could not have 
achieved this without the support of many people at Deakin University and CSIRO-
AAHL. First of all, a huge thank you to Deakin University for offering me a “Deakin 
University Postgraduate Research Scholarship” to support my study. 
 
I would like to express my great appreciation to my principle supervisor A/Prof. John 
Stambas for his support and hard work. John sets a very good example as a scientist. 
He is nice, creative, logical and simplifies complicated issues. These are all very good 
traits for career scientists.  
I would also like to express my gratitude to my co-supervisor Dr Siying Ye for her 
support with experimental protocols, revision of my thesis and day to day advice. As 
old Chinese saying states that my appreciation is more than words alone can say. 
 
I am also grateful to my co-supervisors Dr. Andrew Bean and Dr. Anthony Keyburn for 
their suggestions and research advice. A special thanks to Prof. Alister Ward for his 
invaluable suggestions on this project. 
 
I am extremely grateful to Dr Timothy Doran and Dr. Mark Tizard for supporting this 
chicken gene-editing study. I also want to thank Dr. Arjun Challagulla, Terry Wise, 
Terri O’Neil, Matt Bruce, Tamara Gough, Dr. Kristie Jenkins, Dr. Chwanhong Foo, Dr. 
Andreas Rohringer, Dr. Luis Malaver-Ortega for their help with this project. 
 
I would like to thank lab colleagues past and present; Dr. Leonard Izzard, Dr. Meagan 
McMahon, Dr. Daniel Dlugolenski and Shasha Zhao for creating a wonderful work 
environment for me. 
 
I also appreciate the friendship from Chinese colleagues at CSIRO AAHL; Prof. Linfa 
Wang, Meng Yu, Dr. Jianning Wang, Shuning Shi, Honglei Chen, Dr. Songhua Shan, 
Dr. Pengju Guo, Yu Cao, Dr. Peng Zhou, Jidong Wang and Dr. Qiji Deng. 
 
Finally, I acknowledge my wife Yingju and my son Chengxi for their constant support 
and patience. I also deeply thank my parents, parents-in-law, sister and brother-in-law 
for their support through this journey.  
		
	
 
  
		
	
IV	
 
List of Publications 
 
Manuscripts in preparation 
 
Liu, Q., Ye, S., Challagulla, A., Wise, T., O'Neil, T., Gough, T., Bruce, M., Izzard, L., 
Xia, Y., Jenkins, K., Keyburn, A., Tizard, M., Doran, T., Bean, A., and Stambas, J. 
Efficient enrichment of modified chicken PGCs using CRISPR/Cas9.  In preparation. 
 
Liu, Q., Ye, S., Xia, Y., Dlugolenski, D., Bean, A., and Stambas, J. Characterization 
of influenza virus infection in chicken Interleukin-6 knockout cell lines. In preparation. 
 
Abstract and oral/poster presentations 
 
Oral presentation 
Liu Q., Ye S., Keyburn A., Doran T., Tizard M., Bean A., Stambas J. (2015) 
Understanding the role of IL-6 in influenza A virus infection using CRISPR-mediated 
IL-6 knockout in chicken cell lines. 11th Australian Influenza Symposium, Geelong, 
Australia.  
 
Poster presentation 
Liu Q., Ye S., Challagulla A., Wise T., O'Neil T., Keyburn A., Tizard M., Bean A., Doran 
T., Stambas J. (2016) Efficient enrichment of modified chicken PGCs using 
CRISPR/Cas9. The XXV World's Poultry Congress, Beijing, China 
 
Liu Q., Ye S., Keyburn A., Doran T., Tizard M., Bean A., Stambas J. (2015) Gene 
editing in chickens: knockdown of Interleukin-6 using CRISPR technology. VIIN Young 
Investigator Symposium, Melbourne, Australia. 
   
   
 
  
		
	
 
		
	
V	
Abstract 
	
Chickens are important livestock animals that produce meat and eggs for human 
consumption. They are also an invaluable animal model for biological studies. 
Manipulation of the chicken genome has been difficult and lagged behind advances 
associated with mammalian species. With the development and optimization of 
CRISPR/Cas9 gene editing technology, genes from a range of species have been 
modified. We applied this cutting-edge technology to chicken cell lines and primordial 
germ cells (PGCs). Two chicken cell lines, DF1 and HD11, were used to validate 
CRISPR/Cas9 plasmids designed for human cells. Our results showed that 
humanized CRISPR/Cas9 technology can be used to precisely target the chicken 
genome.  
IL-6 is a highly expressed cytokine associated with morbidity and mortality following 
influenza virus infection in both humans and chickens. Knockout mice are an 
invaluable resource for dissecting pathogenesis and immunity but are not considered 
a natural host for these viruses and so their use, although informative, may not be 
ideal. Herein, we investigated the role of IL-6 in influenza virus immunity using chicken- 
DF1 and HD11 cell lines. ChIL-6-/- DF1 and HD11, generated through CRISPR/Cas9 
gene editing technology were infected with mouse-adapted H1N1 and HP H5N1 
viruses. Results showed higher viral titers were observed in ChIL-6-/- infected cell lines, 
suggesting a protective role for ChIL-6. The in-vivo role of ChIL-6 needs the further 
elucidated using ChIL-6-/+ or ChIL-6-/- chickens. 
The establishment of long-term PGCs cultures in-vitro provides a useful pathway for 
the generation of a modified chicken. Low modification rates have limited PGC use 
and applicability. With rapid development of genome-editing tools, CRISPR/Cas9 
technology has advanced the genome editing field because of its unique ability to 
facilitate multiplex cutting. This means several genetic loci can be modified 
simultaneously by transfecting multiple gRNAs into one cell. We have taken 
advantage of this multiplexed cutting feature to modify GFP and ChIL-6 genes 
simultaneously in GFP-positive PGCs established previously using a Tol2 transposon 
system by the Doran group at CSIRO AAHL. In our study ChIL-6 modified PGCs were 
enriched by flow cytometry (by sorting on GFP-negative PGCs) with 65.0% showing 
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ChIL-6 deletions. This co-targeting strategy has enriched modified PGCs in a simple 
and efficient way and paved the way for the development of a ChIL-6 knockout chicken. 
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Chapter 1   Introduction 
 
1.1 Influenza 
Influenza is an infectious respiratory disease caused by influenza viruses. Influenza 
viruses are part of the Orthomyxoviridae family and are divided into types A, B, C and 
D. Influenza A viruses are further subtyped based on expression of hemagglutinin (HA) 
and neuraminidase (NA) glycoproteins. Of the four subtypes, Influenza A and B 
viruses circulate in humans and cause seasonal epidemics resulting in significant 
morbidity and mortality.  Susceptible populations include the elderly (over 65 years of 
age) and children (younger than 2 years of age) (Cox and Subbarao, 2000). Annual 
epidemics of influenza virus infection cause up to 250,000 to 500,000 deaths and 
result in $87.1 billion in economic losses worldwide (WHO, 2003, Jernigan and Cox, 
2013). Avian influenza viruses (AIV) circulate in avian species and are not normally 
associated with human disease (Connor et al., 1994). However, zoonotic transmission 
does occur from time to time and is associated with high mortality (as noted for H5N1 
and H7N9 viruses) (Yamada et al., 2006, Xiong et al., 2013). H5N1 viruses have 
caused 453 deaths with a mortality rate of 52.7% and H7N9 viruses have caused 559 
deaths with a mortality rate of 37.6% (WHO, 2017, FAO, 2017). 
1.1.1 Influenza virus genome 
Influenza virus are enveloped, negative-sense, single-stranded RNA viruses with eight 
gene segments encoding up to 14 proteins. A diagram of influenza virus structure is 
shown in Figure 1.1. The eight RNA segments are as follows. 
Hemagglutinin (HA) 
The HA gene segment encodes a glycoprotein found on the surface of influenza 
viruses. HA is expressed as a trimer and facilitates entry of the virus into host cells via 
binding to sialic acid receptors on the cell surface. The affinity of HA to the linkages 
between sialic acid and sugar galactose determine species specificity. Human 
influenza viruses bind alpha (2,6) linkages while avian influenza virus prefers alpha 
(2,3) linkages (Rogers et al., 1983).   
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To date, 17 subtypes of HA (H1-H17) have been identified (Fouchier et al., 2005, Tong 
et al., 2012b).  Except for the recently discovered H17 subtype in bats, all other 16 HA 
subtypes can be found in aquatic birds. Currently, only the H1 and H3 subtype viruses 
circulate in a seasonal fashion in humans (Slepushkin et al., 1995, Chen et al., 1998). 
Neuraminidase (NA) 
The NA gene segment encodes the neuraminidase, a tetrameric molecule located on 
the surface of the virus. NA is an enzyme that cleaves sialic acid groups from HA 
glycoproteins, thereby facilitating release of the virus from the host cell. In all, 10 NA 
subtypes (N1–N10) have been identified, where N1 to N9 are found in birds and 
mammals and N10 is exclusively found in bats (Fouchier et al., 2005, Tong et al., 
2012b). The N1 and N2 subtypes are commonly found in seasonal influenza viruses 
circulating in humans (Slepushkin et al., 1995, Chen et al., 1998). 
Polymerase complex 
Acid polymerase (PA), polymerase basic protein 1 (PB1) and polymerase basic 
protein 2 (PB2) are a series of polymerase gene segments that encode the related 
polymerase subunits to form the polymerase complex. PA functions as an elongation 
component to assist RNA synthesis (Fodor et al., 2002). PB1 forms the central domain 
of the RNA polymerase enzyme and is also involved in RNA elongation (Argos, 1988). 
PB2 has the ability to recognize and bind the cap structure of RNA (Fechter et al., 
2003). The polymerase enzyme composed of PA, PB1 and PB2 can catalyze viral 
RNA transcription and replication (Blaas et al., 1982, Li et al., 2001). 
Nucleoprotein (NP) 
The NP gene segment encodes nucleoprotein that binds to individual viral RNAs, 
which then interact with the viral polymerase subunits, PA, PB1, and PB2, to form 
ribonucleoprotein (RNP) complexes; initiating RNA transcription, replication and 
packaging (Portela and Digard, 2002). In addition, NP serves as a vital adaptor 
molecule between the cell and virus through its interactions with cellular and viral 
macromolecules such as RNA and matrix protein (Portela and Digard, 2002). 
 
		
	
3	
Matrix protein (M)  
The M gene segment encodes two proteins (M1 and M2) using alternate reading 
frames from the same RNA segment. The M1 protein is involved in virus assembly 
and budding by binding both viral RNA and membrane proteins (Ruigrok et al., 2000), 
whereas the M2 protein encodes an ion channel on the surface of the viral envelope 
and is thought to play an key role in initiating viral uncoating through manipulation of 
pH in the endosome (de Jong and Hien, 2006, Betakova, 2007). 
Non-structural proteins (NS)  
The NS gene segment also encodes two distinct proteins (NS1 and NEP/NS2) using 
alternate reading frames (similar to the M gene segment) to generate two proteins. 
The NS1 protein serves as an interferon-agonist to benefit virus replication, and the 
nuclear export protein (NEP) is thought to guide the newly synthesized RNP out of the 
nucleus (LU et al., 1995, O'Neill et al., 1998).  
 
Figure 1.1. Figure of influenza A virus structure. The influenza virus genome includes eight gene 
segments. The surface of influenza virion is coated by HA, NA and M2 (Horimoto and Kawaoka, 2005).  
1.2 Avian influenza virus pathogenicity  
The virulence of AIV in avian species is defined as high pathogenicity (HP) if it meets 
one or more of the three following criteria: (i) the influenza virus causes death in ≥75% 
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of cases within 10 days in four to six-week-old intravenously infected chickens ; (ii) 
any H5 or H7 subtype virus that does not meet the criteria in section (i), but has a 
similar amino acid motif at the HA cleavage site (a known virulence determinant) with 
other high pathogenicity avian influenza isolates; and (iii) any influenza virus, 
excluding H5 or H7 subtypes, that can cause death in <75% of chickens within 10 
days but can grow in cell culture without the addition of an exogenous HA cleavage 
enzyme (such as trypsin). An AIV that does not meet any of these three criteria is 
classified as low pathogenicity (LP) (Swayne and Suarez, 2000). Apart from infecting 
avian species, AIV can also infect humans and other species in rare zoonotic spill-
overs (Alexander, 2000). The pathogenicity of AIVs in humans varies depending on 
the strain of virus. For a long time, it was thought that only HP AIV strains can be 
associated with pandemics or zoonotic outbreaks in humans following cross-species 
transmission and adaptation, i.e. H5N1. However, newly emerged LP AIV H7N9 
strains (A/Anhui/1/2013 and A/Shanghai/1/2013) can transmit from birds to humans, 
causing morbidity and mortality, clearly demonstrating that the abovementioned 
correlation may not be appropriate for all situations (Gao et al., 2013). 
1.2.1 Avian influenza pathogenicity in aquatic avian species 
As the natural host of AIV, some aquatic avian species, such as ducks, geese, and 
swans, co-exist with influenza viruses in the environment and LP AIV infection typically 
shows no or very mild pathological lesions (Olsen et al., 2006, Yoon et al., 2014). LP 
AIV infection in aquatic birds has been reviewed by Yoon et al., 2014. LP AIV usually 
infects intestinal epithelial cells in these reservoir birds, and is characterized by a rapid 
turnover of virus-infected cells (Pantin-Jackwood and Swayne, 2009). This rapid cell 
death is beneficial for the virus, allowing excretion/shedding, and also aids host 
recovery (Daoust et al., 2011). The host immune response in waterfowl following 
infection is generally limited, exemplified by the lack of inflammatory cells around foci 
of infection and low level antibody titers (Daoust et al., 2011).  
The pathogenicity of HP AIV in waterfowl has evolved over time and pathogenicity has 
altered. HP AIV H5N1 isolated from the 1997 outbreak (A/Hong Kong/156/97 and 
A/chicken/Hong Kong/258/97) do not replicate efficiently in ducks, and infected ducks 
show no clinical signs or change in food consumption (Subbarao et al., 1998). 
However, outbreaks of HP AIV H5N1 (A/Goose/HK/739.2/02) in Hong Kong in late 
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2002 caused the death of wild and domestic aquatic birds including ducks (Ellis et al., 
2004). Susceptible species show severe necrosis and inflammation in multiple organs, 
such as the pancreas, lungs, brain, liver, heart and adrenal glands (Ellis et al., 2004). 
Moreover, the H5N1 viruses isolated from 2003 and 2004 shed from the upper 
respiratory tract rather than intestinal epithelial cells of ducks (Sturm-Ramirez et al., 
2004). In 2005, a more significant outbreak of H5N1 (A/Bar-headed 
Goose/Qinghai/12/05) in migratory birds occurred on Lake Qinghaihu in Western 
China, resulting in more than 6000 diseased or dead birds with pancreatic necrosis 
and abnormal neurological symptoms (Liu et al., 2005). This outbreak was considered 
the source of further spread of H5N1 virus to Africa and other European countries (Liu 
et al., 2005, Chen et al., 2005, Neumann et al., 2009). Despite the fact that the 
pathogenicity of HP strains in wild aquatic birds have been identified, the 
overwhelming view in the field is that some species, especially mallards, 
asymptomatically maintain these HP AIVs in nature (Keawcharoen et al., 2008).  
1.2.2 Avian influenza pathogenicity in poultry 
In poultry, LP AIV infection typically shows sub-clinical symptoms, such as sneezing, 
fever, depression, and decreased egg production in chickens and turkeys (Hooper and 
Selleck, 2003). Mild pathological lesions and conditions including tracheitis, bronchitis 
and broncho-interstitial pneumonia can be found in the trachea and the lung (Reperant 
et al., 2012). In experimental infections, specific-pathogen-free laying hens 
intravenously inoculated with LP A/Chicken/Alabama/7395/75 (H4N8) showed 
additional lesions in the reproductive and urinary tract, including atrophy and 
inflammation of the ovaries and oviducts, renal necrosis and inflammation (nephritis), 
and bursal necrosis (Shalaby et al., 1994).  
In contrast, HP AIV infection spreads systemically in poultry and causes large lesions 
in multiple organs. The common clinical symptoms of chickens infected with HP AIV 
include oedema or necrosis of the comb and wattle, oedema in the head and legs, 
subcutaneous haemorrhage of legs, pulmonary haemorrhage and oedema, and small 
haemorrhages in internal organs (Jeong et al., 2009, Pfeiffer et al., 2009, Hagag et al., 
2015). Chickens typically die within 48 hours of infection, and may in some cases, 
show few visible clinical signs (OIE, 2012). The high morbidity and mortality rate 
following HP IAV infection causes large economic losses to the poultry industry. During 
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the outbreak of HP AIV H5N1 between 2004 and 2005 in Asia, over 150 million 
domestic birds were culled, resulting in a total $10 billion loss (Hinrichs et al., 2006). 
1.2.3 Avian influenza pathogenicity in humans 
In humans, zoonotic transmission and infection by LP AIVs, such as H9N2, causes 
mild respiratory symptoms, including fever, coughing, sore throat, decreased appetite, 
abdominal pain and vomiting (Guan et al., 1999, Lin et al., 2000). These cold-like 
symptoms following LP AIV infection mimic human seasonal influenza and infected 
individuals generally recover quickly (Peiris et al., 1999). Two AIV strains (H5N1 and 
H7N9) however cause severe disease in humans. HP H5N1 infection of humans was 
first reported in 1997 and caused the death of six of eighteen infected patients (Claas 
et al., 1998, Yuen et al., 1998). In 2003, HP H5N1 re-emerged in Hong Kong and 
spread worldwide (Peiris et al., 2004). Patients presented with multiple organ failure 
consisting of diffuse alveolar damage in the lung, apoptotic lymphocytes in the spleen 
and intestinal tract and showed liver abnormalities (Korteweg and Gu, 2008). Further 
investigation revealed that rapid replication of HP H5N1 virus triggered expression of 
high levels of cytokines (“cytokine storm” or hypercytokinemia), leading to acute 
inflammatory tissue damage and destruction of alveolar function (de Jong et al., 2006). 
In 2013, a novel LP H7N9 strain infected humans in China (Control and Prevention, 
2013)  and has infected 1525 individuals to date(FAO, 2017). Clinical symptoms in 
H7N9-infected individuals include coughing, high fever, and pneumonia. Respiratory 
failure is observed in the severely infected patients leading to death (Tang and Chen, 
2013). A cytokine storm similar to that observed in  HP H5N1 infections is also 
observed in LP H7N9 cases as seen (Chen et al., 2013c). Unlike HP H5N1, LP H7N9 
is low pathogenic in chickens (Shi et al., 2013). H7N9 has also shown enhanced 
mammalian adaptation, which may account for its pathogenicity in humans. It contains 
a Q226L mutation in the HA protein, enhancing its ability to bind mammalian-like 
receptors (Matrosovich et al., 2004). As such, concerns regarding potential human-to-
human transmission of H7N9 have been raised by many experts (Zhu et al., 2013). 
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1.3 Immune responses to Influenza infection  
In vertebrates there are two basic defense systems to eliminate pathogens: the innate 
and the adaptive immune systems (Takeda et al., 2003). The innate immune system 
recognizes conserved components of invading pathogens via pattern recognition 
receptors (PRRs) (Medzhitov, 2007). This rapid and efficient innate immune response 
can protect the host from most organisms. The adaptive immune response is required 
to eliminate pathogens and to ensure establishment of immunological memory to 
prevent reinfection (Bogs et al., 2010). Influenza infection of epithelial cells initiates 
host immune responses (Ramos et al., 2011). Intracellular PRRs are activated, 
including Toll-like receptor (TLR) 3 and TLR7 (Baskin et al., 2009). Activation of PRRs 
triggers the secretion of type I interferon and proinflammatory cytokines (Alexopoulou 
et al., 2001, Heil et al., 2004). These cytokines act to inhibit viral replication at the site 
of infection and link the innate and adaptive immune response (Heil et al., 2004). As 
a key focus of this thesis is immunity against avian influenza viruses we will review the 
interactions between the host and H5N1 viruses below. 
The immune responses to HP H5N1 infection have been characterized in multiple 
animal models including mice, ferrets and nonhuman primates (Maines et al., 2008, 
Peiris et al., 2009). In mice, HP H5N1 infection reduces	interferon-g and interleukin-1β 
expression and results in a decrease in the number of CD4+ and CD8+ T cells in lung 
(Tumpey et al., 2000). Ferrets infected with HP H5N1 virus (A/Vietnam/1203/04) show 
robust expression of interferon response genes such as CXCL10 (Cameron et al., 
2008). Chemical inhibition (AMG487) of the CXCL10 receptor ameliorates the severity 
of HP H5N1 infection (Cameron et al., 2008). From an evolutionary point of view, 
nonhuman primates are the best animal model to study HP H5N1 infection. Clinical 
signs of HP H5N1 infection in primates is similar to that observed in humans. HP H5N1 
(A/Vietnam/1203/04) infection in primates results in increased cytokine expression 
(type I Interferon, IL-1, IL-6 and TNF-α ) and lower numbers of circulating CD4+ and 
CD8+ T cells (Baskin et al., 2009). 
Unlike other animal models, the chicken is naturally susceptible to HP H5N1 infection 
and can directly transmit HP H5N1 to humans. In chickens infected with HP AIV H5N1 
(A/chicken/Yamaguchi/7/04), expression of antiviral cytokines (IFN-α and IFN-β) and 
proinflammatory cytokines (IL-6, IL-8 and IL-15) increases rapidly 12 hours post-
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infection and peaks at 24 hours post-infection (Suzuki et al., 2009). High virus titers 
and robust expression of proinflammatory cytokines (IL-1b, IL-6, IL-18 and IFN-g) are 
also observed in chickens infected with HP H5N1 strain	 (A/Muscovy 
duck/Vietnam/453/2004) (Burggraaf et al., 2014). Notably, IL-6 expression is highly 
expressed in multiple organs following HP H5N1 infection of chickens (70 fold higher 
in lung, 100 fold higher in liver, 80 fold higher in spleen) compared to uninfected 
controls (Burggraaf et al., 2014). 
In the initial 1997 HP H5N1 outbreak, patients expressed high levels of IL-2, IL-6, TNF-
a and IFN-g in their blood samples (To et al., 2001). Re-emergence of HP H5N1 in 
2003 resulted in elevated serum chemokines (such as IFN-inducible protein 10, 
monokine induced by IFN-g ) in infected individuals (Peiris et al., 2004). Detailed 
analyses of 18 infected patients in 2004-2005 revealed high plasma concentrations of 
IL-10, IL-6 and IFN-g when compared to healthy controls (de Jong et al., 2006). Virus 
titers in patients correlated with cytokines levels and determined the outcome of 
infection (de Jong et al., 2006). Data from these studies highlights how aberrant 
expression of cytokines contributes to the pathogenicity of H5N1 infection in humans.  
1.3.1 Hypercytokinemia  
Hypercytokinemia, or ‘cytokine storm’, is a term describing a dysregulated 
inflammatory immune response in the host. Cytokine storms can be induced by a wide 
range of non-infectious and infectious diseases such as severe acute respiratory 
syndrome coronavirus (SARS-CoV) infection (Huang et al., 2005), and pancreatitis 
(Makhija and Kingsnorth, 2002) and are thought to contribute to mortality in HP AIV 
H5N1-infected patients , as well as in severe H7N9 cases (Chen et al., 2013c). A 
'cytokine storm' involves a large number of cytokines including interferons, interleukins, 
chemokines, TNFs and colony-stimulating factors (CSFs) (Tisoncik et al., 2012). High 
levels of IL-6 have been observed following H5N1 and H7N9 infection and are thought 
to contribute to cytokine storm (Alam et al., 2012, Chi et al., 2013). 
IL-6 is a 26-KDa protein which can be expressed by a large range of cells including 
macrophages, endothelial cells, fibroblasts, B and T cells. IL-6 is involved in multiple 
biological processes as indicated by its historical names including B cell stimulation 
factor 2 (BSF2) (Teranishi et al., 1982), cytotoxic T cell differentiation factor (CDF) 
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(Teranishi et al., 1982) and IFN-b2 (Weissenbach et al., 1980). Like mammalian IL-6, 
chicken IL-6 (ChIL-6) is a pleotropic cytokine although it differs in terms of 
chromosomal location and structure. The ChIL-6 gene is located on chromosome 2 
(compared with chromosome 7 in mammals) and consists of four exons and three 
introns (compared with five exons and four introns in mammals). The ChIL-6 gene 
encodes a 241-amino acid protein and shares approximately 35% homology with 
mammalian IL-6. Analysis of the ChIL-6 promoter region indicates the presence of 
upstream regulators similar to those found in mammals, including the glucocorticoid 
response element (GRE), an activator protein 1 (AP-1) binding site, a nuclear factor 
kB (NF-kB) binding site, an NF-IL-6 binding site, a second AP-1 binding site and a 
TATA box (Kaiser et al., 2004). 
1.3.2 IL-6 signaling 
IL-6 signaling has only been characterized in mammalian species (Figure 1.2) and 
very little is known about signaling in chickens. In mammalian species, IL-6 signals 
through the IL-6 receptor, which consists of two subunits: the IL-6 receptor alpha 
subunit (also known as CD126) and the IL-6 signal transducer (gp130), a subunit 
shared by other IL-6 cytokine family members (Heinrich et al., 1998). In contrast to the 
broad expression of gp130, IL-6 receptor alpha is confined to hepatocytes, leukocyte 
subsets and megakaryocytes. The binding between IL-6 and its receptor initiates a 
signaling cascade, that involves activation of janus kinase (JAK) and Ras-mediated 
signaling. Activated JAKs activate signal transducers and activators of transcription 
(STATs), especially STAT3 and Src homology-2 domain-containing tyrosine 
phosphatase (SHP2) (Ichiba et al., 1998, Hirano et al., 2000). Phosphorylated STATs 
then dimerize and translocate into the nucleus to activate the transcription of genes 
containing STAT response elements. In addition to the JAK/STAT signaling pathway, 
IL-6 signaling is also involved in the Ras/MAP (mitogen-activated protein) kinase 
pathways via Src homology 2 domain containing (SHC) and growth factor receptor 
bound protein-2 (GRB2). Ras can then activate the transcription factor extracellular 
signal-regulated kinase (ERK) which acts through its response elements in the 
genome (Ichiba et al., 1998). Feedback inhibition of the IL-6 signaling pathway occurs 
through the up-regulation of the suppressor of cytokine signaling (SOCS) to inhibit 
JAK kinase (Pfitzner et al., 2004). 
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Figure 1.2. IL-6 signaling pathway.	(i) JAK/STAT pathway (ii) Ras/MEK pathway (Moya et al., 
2011).  
 
1.3.3 IL-6 and innate and adaptive immunity  
IL-6 plays an important role in both innate and adaptive immune responses and is 
thought to contribute to disease when dysregulation occurs. In the initial phase of viral 
infection, IL-6, together with IL-1β and tumor necrosis factor-α (TNF-α), are expressed 
and drive production of various chemokines, which results in the attraction of 
neutrophils (Scheller et al., 2011). IL-6 then functions as a key mediator in the 
transition from innate to adaptive immunity via inhibiting neutrophil-attracting and 
enhancing monocyte-attracting chemokines, leading to a switch from neutrophil to 
monocyte recruitment (Jones, 2005). IL-6 also plays a key role in B and T cell 
differentiation. In IL-6-/- mouse, immunoglobulin G (IgG) production is impaired 
following immunization with a T cell-dependent antigen (Boulanger et al., 2003). IL-6 
has also been found to induce the formation of IL-17-secreting TH17 cells, which are 
a subset of T helper cells related to autoimmune disease (Bettelli et al., 2006). A range 
of autoimmune and chronic inflammatory proliferative diseases have been associated 
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with dysregulated IL-6 production, including systemic-onset juvenile chronic arthritis, 
systemic lupus erythematosus and Castleman’s disease (Ishihara and Hirano, 2002). 
Therefore, IL-6 has become a target molecule for the treatment of severe inflammation, 
which will be discussed below. 
1.3.4 Anti-IL-6 therapy 
The involvement of IL-6 in arthritis have been investigated using IL-6-/- mice and has 
provided powerful evidence that IL-6 can serve as a drug target. IL-6-/- mice have less 
severe disease in collagen-induced arthritis (CIA) or can be resistant to the 
development of CIA (Sasai et al., 1999). In addition, Yoshizaki and colleagues 
demonstrated that blocking the IL-6 receptor effectively inhibits the formation of CIA 
(Yoshizaki et al., 1998). In light of these results, the first anti-IL-6 reagent, Tocilizumab, 
for clinical trials was developed. Tocilizumab is a monoclonal antibody that targets 
human IL-6 receptors and can ameliorate the clinical syndromes of Rheumatoid 
Arthritis (RA), such as reducing radiographic joint damage and inhibiting B cell 
hyperactivity (Choy and Sattar, 2009, Roll et al., 2011). Currently, several other anti-
IL-6 therapies are in clinical trial, such as CNTO 136 (antibody targeting IL-6 to treat 
RA), CNTO 328 (antibody targeting IL-6 to treat prostate cancer) and CR5/18 (an 
antagonist of IL-6R signaling) (Kopf et al., 2010). In addition to monoclonal antibodies, 
some chemical compounds have been found that have the ability to interfere with IL-
6 signaling pathway, such as madindoline-A (Mad-A) and galiellalactone (Gal). Mad-
A can inhibit the production of IL-6-mediated proteins (such as serum amyloid A) by 
binding to gp130, and Gal can hinder IL-6 function by targeting STAT (Weidler et al., 
2000, Hayashi et al., 2002). 
1.3.5 Interleukin-6 and influenza virus infection 
High levels of IL-6 have been found in bronchoalveolar lavage fluid (BALF) of patients 
infected with H5N1 who died from acute respiratory distress syndrome (ARDS) 
compared with those who survived, suggesting that the IL-6 may contribute to the 
severity of lung inflammation (de Jong et al., 2006). Moreover, Kaiser and colleagues 
observed that the level of IL-6 in serum and nasopharyngeal lavage fluid of patients 
positively correlated with the severity of syndrome scores and body temperatures 
(Kaiser et al., 2001). Studies have shown that the level of IL-6 in serum are significantly 
		
	
12	
higher in patients infected with viruses such as H7N9 when compared to healthy 
controls (Chen et al., 2013c, Zhou et al., 2013). These studies suggest that high 
expression of IL-6 may contribute to high pathogenicity following H5N1 or H7N9 
infection. Thus far, a clearly defined role for IL-6 in the pathogenesis of influenza virus 
infection is still unclear (La Gruta et al., 2007). Infection of IL-6-/- mice, suggests that 
IL-6 plays a protective role during influenza infection by modulating the host innate 
and adaptive immune responses (Dienz et al., 2012, Lauder et al., 2013). Dienz et al. 
show that IL-6-/- mice exhibit longer recovery times and higher mortality rates due to a 
reduced number of infiltrating neutrophils to the lung, leading to slower virus clearance 
(Dienz et al., 2012). On the other hand, Lauder et al. proposed that as IL-6 plays an 
important role in limiting inflammation and promoting adaptive immunity (Lauder et al., 
2013).   
In chicken cell lines, ChIL-6 is highly expressed following AIV infection, when 
compared with duck cell lines (generally resistant to infection) (Suzuki et al., 2009, Ye 
et al., 2015). Similar to in vitro studies, robust expression of ChIL-6 was observed in 
chickens infected with HP H5N1(A/Muscovy duck/Vietnam/453/2004) when compared 
to those infected with LP H5N3 (A/Duck/Victoria/1462/2008) (Burggraaf et al., 2014). 
Furthermore, by comparing the pathogenicity of H5N1 (A/Muscovy 
duck/Vietnam/453/2004) between chickens and ducks, a positive correlation was 
found between the severity of infection and ChIL-6 expression levels (Burggraaf et al., 
2014). This dysregulation of ChIL-6 in chickens following H5N1 infection resembles 
the clinical signs of humans H5N1 or H7N9 infection. Therefore, understanding the 
role of ChIL-6 in the chicken (a natural host) will provide vital information for the 
development of intervention strategies for humans. 
1.4 Genome editing technology 
Genome editing involves introducing changes into cellular genomic DNA in an attempt 
to reprogram the cellular biological system. A classical method of altering gene 
function is silencing genes of interest via homologous recombination (HR) (Capecchi, 
2005). However, this method has limited application due to the low gene-targeting 
efficiency and labor-intensive selection processes (Walsh and Hochedlinger, 2013). In 
order to understand the relationship between genotype and phenotype, more feasible 
and efficient approaches have been developed for the manipulation of genomes 
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without relying on natural spontaneous mutagenesis or HR. Previous reports have 
shown that the frequency of homology-directed repair (HDR) can be increased by the 
introduction of double-strand breaks (DSB) on genomic DNA using chimeric nucleases 
(Wyman and Kanaar, 2006). With the advent of novel synthetic nucleases, several 
robust, efficient and economical tools have been recently employed to allow for the 
generation of knockout/knockin animal models (Gaj et al., 2013). Below, we briefly 
review three effective technologies: (i) zinc finger nucleases (ZFNs), (ii) transcription 
activator-like effector nucleases (TALENs) and (iii) clustered regularly interspaced 
short palindromic repeats/CRISPR-associated protein (CRISPR/Cas).  
1.4.1 Zinc finger nucleases (ZFNs) 
ZFNs consist of two functional domains, the zinc finger DNA-binding domain and the 
cleavage domain that contains the type II restriction endonuclease Fok I. These 
domains allow ZFNs to target unique sequences and to precisely cleave DNA within 
a genome (Figure 1.3 A) (Kim et al., 1996). The zinc finger domain contains the most 
common DNA-binding motif in eukaryotes with a ββα configuration, that allows ZFNs 
to be engineered to bind to specific DNA sequences. Usually, a zinc finger domain can 
recognize three specific nucleotides; hence, a pair of 3-finger ZFNs that recognize 18 
base pairs (bps) is enough to target a single locus in the mammalian genome (Beerli 
et al., 1998). The zinc finger domain is linked to the cleavage domain (Fok I) at the C-
terminus and spaced by 5 – 7 bps. Dimerization of the cleavage domain confers 
endonuclease activity that cleaves target DNA (Kim et al., 1996, Bitinaite et al., 1998).  
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Figure 1.3. Structure and design of ZFNs. (A) Sketch of ZFN dimers bound to their target. Two ZFN 
proteins (ZFP) bind to target DNA sequences. The target site is cleaved when the cleavage domains 
containing endonuclease Fok I dimerize. (B) Modular assembly. Three individual fingers with their 
specific target sequence are linked together to generate a zinc finger protein targeting GGGGGTGAC 
(Urnov et al., 2010).  
 
1.4.1.1 Construction of ZFNs 
A number of strategies have been developed to construct ZFNs. The classical 
approach, called ‘modular assembly’, requires linking of several single fingers to form 
a multi-finger peptide that targets a specific sequence (Figure 1.3B) (Segal et al., 
2003). Most triplet-sequence modules have been developed by this strategy (Segal et 
al., 1999, Bae et al., 2003). Several novel approaches to generate target-specific ZFNs 
have also been developed. A method known as ‘oligomerised pool engineering’ 
(OPEN) is used to select desired ZFNs from randomized libraries (Maeder et al., 2008). 
Another method is ‘context-dependent assembly’ (CoDA), which is a platform to 
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construct ZFNs based on previously validated work using only standard cloning 
techniques (Sander et al., 2010). Testing of 38 CoDA-generated ZFNs in zebrafish 
and plants achieved a 50% success rate for obtaining mutations, which is comparable 
to that of OPEN (67%) (Sander et al., 2010).  
1.4.1.2 Application of ZFNs 
ZFN-mediated genomic modification has been applied to many research fields and 
various species, including Arabidopsis (Zhang et al., 2010a, Osakabe et al., 2010), 
tobacco (Cai et al., 2009, Townsend et al., 2009), soybean (Curtin et al., 2011), corn 
(Shukla et al., 2009), flies (Bibikova et al., 2003), C. elegans (Wood et al., 2011), sea 
urchins (Ochiai et al., 2010), silkworms (Takasu et al., 2010), zebrafish (Ekker, 2008), 
frogs (Young et al., 2011), mice (Carbery et al., 2010), rats (Geurts et al., 2009), 
rabbits (Flisikowska et al., 2011), pigs (Hauschild et al., 2011) and cattle (Yu et al., 
2011) and various mammalian cells. ZFNs have been used to disrupt expression of 
the chemokine receptor type 5 (CCR5) gene in CD4+ human T cells as a potential 
human immunodeficiency virus infection/acquired immunodeficiency syndrome 
(HIV/AIDS) therapeutic (Perez et al., 2008, Holt et al., 2010). The efficiency of ZFNs 
targeting CCR5 has exceeded 50% in both cell lines and primary human CD4 T cells 
using an adenoviral delivery system (Perez et al., 2008). However, a number of issues 
will need to be addressed to extend this therapeutic application, particularly improving 
specificity, and reducing off-target cleavage and cytotoxicity (Urnov et al., 2010). 
1.4.2 Transcription activator-like effector nucleases (TALENs) 
TALENs are chimeric nucleases fused by a group of TAL effector proteins that were 
originally discovered in the plant pathogenic bacterial genus Xanthomonas (Boch and 
Bonas, 2010, Miller et al., 2010). The binding domain of TALENs consists of repeated, 
highly conserved 33-34 amino acids with two variable amino acids (12th and 13th) 
which function as the target recognition region; termed repeat variable diresidue (RVD) 
(Boch et al., 2009, Moscou and Bogdanove, 2009). The relationship between amino 
acid sequence and DNA recognition can be summarized as NI(Asn Ile) = A, NN(Asn 
Asn)/NK(Asn Lys) = G, NG(Asn Gly) = T, HD(His Asp) = C (Figure 1.4A) (Moscou and 
Bogdanove, 2009). It has been shown that NH has a higher affinity to G than NN 
(Streubel et al., 2012). Similar to ZFNs, a pair of specifically designed TALENs will 
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bind the cleavage site and the Fok I enzyme functions to cut the genome after 
dimerization (Figure 1.4B).  
 
Figure 1.4. Structure and construction of TALENs. (A) Sketch of a single TALEN. It consists of a 
nuclear localization signal (NLS, blue); a recognition domain composed of tandem TALE repeats (green); 
and a C-terminal domain linked endonuclease Fok I (black). Each TALE repeat comprises of a highly 
conserved 33-34 amino acid sequence with two variable amino acids (12th and 13th) that function as 
the recognition region: NG (recognizing T), NI (recognizing A), HD (recognizing C), or NN/NK 
(recognizing G) (colour boxes). (B) Sketch of TALEN dimers bound to their target. Two TALEN proteins 
fused with endonuclease Fok I bind to their target and Fok I cleaves DNA strands to cause DSB 
following Fok I enzyme dimerization. (C) Construction of TALEN plasmids using the one-step Golden 
Gate cloning method. The plasmid pool includes 424 TAL effector array plasmids (64×6+16×2+4×2) 
and 8 Fok I plasmids. (Wei et al., 2013, Kim et al., 2013).  
 
1.4.2.1 Construction of TALENs 
The highly repetitive nature of TALENs provides challenges for the construction of 
customized reagents. The 'standard restriction assembly method' using standard 
restriction enzyme digestion and ligation reactions has been successfully used in 
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different model organisms (Huang et al., 2011, Sander et al., 2011). However, this 
method is laborious and time-consuming and hinders the wide-scale application of 
TALENs (Wei et al., 2013). Subsequently, a one-step Golden Gate cloning system 
was developed using a library pool of 424 TAL effector array plasmids and 8 Fok I 
plasmids (Figure 1.4C), which facilitate more efficient TALEN construction (Kim et al., 
2013). The procedure is to choose the intended plasmids with the corresponding 
recognition domain at each position and then ligase them together into Fok I vector 
using their own specific 4-bp overhangs. A modified method based on the Golden 
Gate cloning strategy is further developed with the advantage of being fast, simple 
and economically viable (Cermak et al., 2011, Li et al., 2011, Sander et al., 2011, 
Zhang et al., 2011). In simple terms, this approach makes use of type IIS restriction 
enzymes to generate multiple sticky ends for ligation into one plasmid (Cermak et al., 
2011). Moreover, four high-throughput TALEN assembly methods have been 
developed to avoid standard cloning procedures, such as transformation, ligation and 
selection of positive bacterial clones. These methods include fast ligation-based 
automatable solid-phage high-throughput (FLASH) (Reyon et al., 2012), iterative 
capped assembly (ICA) (Briggs et al., 2012), chip (Wang et al., 2012) and ligation 
independent cloning (LIC) (Schmid-Burgk et al., 2012). These high-throughput 
methods have the ability to generate multiple TALENs in less than a day, providing a 
powerful tool for further genome-wide scale modification (Chen and Gao, 2013).  
1.4.2.2 Application of TALENs 
TALENs technology has been tested in a variety of organisms and cell lines, including 
plants (Christian et al., 2010, Li et al., 2012), rats (Tesson et al., 2011, Tong et al., 
2012a), frogs (Lei et al., 2012), zebrafish (Sander et al., 2011, Huang et al., 2011, Zu 
et al., 2013), worms (Wood et al., 2011), flies (Liu et al., 2012, Kondo et al., 2013), 
mice (Sung et al., 2013), livestock (Carlson et al., 2012), human pluripotent stem cells 
(Hockemeyer et al., 2011) and human somatic cells (Cermak et al., 2011). These 
experiments have proven TALENs technology is an efficient and feasible genome-
engineering tool. In addition, the studies comparing TALENs and ZFNs have shown 
that TALENs are more effective at targeting and mutating zebrafish and Drosophila 
genomes (Beumer et al., 2013, Chen et al., 2013b). TALEN technology was also 
applied in chickens to generate ovalbumin (OV) gene-knockouts (Park et al., 2014). 
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1.4.3 Clustered regularly interspaced short palindromic repeats/Cas (CRISPR/ 
Cas)  
The CRISPR/Cas system was optimized for application in eukaryotic cells in late 2012. 
This system was originally developed from components of a bacterial immune system 
to target and destroy foreign DNAs. There are three main components of the 
CRISPR/Cas system; Cas9 protein, CRISPR RNA (crRNA) and trans-activating 
CRISPR RNA (tracrRNA). Cas9 protein is a nuclease that can cleave double-strand 
DNA. crRNA is a 20-nucleotide sequencing that can recognize the specific targets 
through Watson-Crick base-pairing (Brouns et al., 2008, Jinek et al., 2012). The 
structure of tracrRNA is a hairpin loop and it can bind crRNA to form a 
ribonucleoprotein complex (crRNA-tracrRNA-Cas9). A short conserved sequence 
NGG, called the protospacer adjacent motif (PAM) located at the 3¢-terminal of the 
target gene is required for ribonucleoprotein complex to function. The main 
components of CRISPR/Cas system are shown in Figure 1.5.  
 
Figure 1.5 Sketch of CRISPR bound to its target. crRNA and tracrRNA together function as the guide 
RNA to direct Cas9 protein to bind their target locus via Wastson-Crick base-pairing. The cleavage 
function of Cas9 protein depends on a PAM (NGG) structure that is located immediately down-stream 
of the target locus (Wei et al., 2013). 
 
1.4.3.1 Construction of CRISPR/Cas9 
The construction of a CRISPR/Cas9 system is simple and continues to be simplified 
with additional features incorporated into the system for high-throughput screening of 
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modified clones. At first, a system was developed where the crRNA and tracrRNA 
were fused into a single RNA, called the guide RNA (gRNA), (Gratz et al., 2013, Yu et 
al., 2013, Bassett et al., 2013). Plasmids for expressing gRNA can be easily and 
rapidly generated by ligating short pairs of oligonucleotides into a gRNA vector, and 
Cas9 protein can be expressed from commercially available vectors (Hwang et al., 
2013). Recently, the CRISPR/Cas9 system has been further streamlined by fusing the 
gRNA and Cas9 into one vector, increasing the efficiency of transfection (Ran et al., 
2013b). To screen positively transfected cells, the Cas9 protein has been fused with 
2A-GFP (a 2A cleavage site and a green fluorescent protein) or 2A-puromycin to allow 
screening or drug selection of transfected cells (Ran et al., 2013b). A detailed protocol 
for genome editing using the CRISPR/Cas9 system has been published in Nature 
Protocols, providing a step-by-step guide to the construction of CRISPR/Cas9 and 
describes designing gRNA targets and screening of modified cells (Ran et al., 2013b).  
In order to reduce the off-target effects of the CRISRP/Cas9 system, Cas9 nuclease 
variants have been generated by mutating one or both of its two catalytic domains. 
Cas9 nickase (Cas9n) is an engineered nuclease carrying one catalytic domain 
mutation with the ability to cleave only one strand of DNA (Mali et al., 2013a, Ran et 
al., 2013a). As such, two Cas9n proteins that target two different sequences that are 
0 – 20 base pair apart are required to produce DSBs to initiate the cell repair process. 
Cas9n therefore significantly decreases off-target frequency because both Cas9n 
proteins have to bind specific target sequences. The off-target break generated by 
either Cas9n can be repaired through the endogenous base-excision repair pathway 
with little damage to the genome. Undetectable off-target frequency can be achieved 
as demonstrated in previous studies (McCaffrey et al., 2016, Mikami et al., 2016, 
Trevino and Zhang, 2014). Another variant of Cas9, nuclease deactivated Cas9 
(dCas9) or CRISPR interference, is generated through the disruption of both Cas9 
catalytic domains (Wu et al., 2014). Binding of dCas9 to the target gene can block the 
transcription process, resulting in the silencing or activation of endogenous gene 
expression. The dCas9 has the potential to over-express or block protein expression 
in cells through transfection of plasmids (Tanenbaum et al., 2014).  
The CRISPR/Cas9 system outperforms ZFNs and TALENs as it facilitates multiplexed 
cutting (Cong et al., 2013). Multiple gRNAs can be transfected into cells to target 
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different gene loci simultaneously. In practice, a maximum of seven genes can be 
targeted by the CRISPR/Cas9 system in one transfection (Sakuma et al., 2014). 
Biological phenotypes and disease development usually involve the orchestrated 
action of multiple genes. The discovery of phenotype-related genes is a time-
consuming and labor-intensive challenge. The combination of CRISPR/Cas9 
technology and lentiviral delivery vectors can express thousands of gRNA pool into 
human cells at the same time and the disease-related genes can be further identified 
through high-throughput sequencing analysis of cells with corresponding phenotypes 
(Wang et al., 2014b, Koike-Yusa et al., 2014).  
1.4.3.2 Application of CRISPR/Cas9 
Over the past three years, the CRISPR/Cas9 system has been successfully applied 
to edit the genome of cultured mammalian cells (Cho et al., 2013, Cong et al., 2013, 
Jinek et al., 2013, Mali et al., 2013b), zebrafish (Hwang et al., 2013, Auer et al., 2013, 
Hruscha et al., 2013), Drosophila (Ren et al., 2013, Gratz et al., 2013), plants (Belhaj 
et al., 2013, Shan et al., 2013), mice (Wang et al., 2013), monkey (Wan et al., 2015) 
and even human embryos (Liang et al., 2015). Traditionally, knockout mice are 
established by modifying embryonic stem cells, which is time-consuming and 
expensive, especially when generating multiple gene-modified mice. Recently, 
CRISPR/Cas9 technology has been employed to produce genetically modified mice 
rapidly and efficiently. Many groups have developed one-step approaches to generate 
mice carrying multiple mutations using CRISPR/Cas9 technology (Wang et al., 2013, 
Yang et al., 2013, Zhou et al., 2014). Cas9 mRNA and gRNAs co-transfected into mice 
zygotes simultaneously at the blastocyst stage. The blastocysts are then transplanted 
into surrogate female mice. Pups carrying the mutations are then screened using 
southern blot and sequencing analysis, with the whole process taking approximately 
one month. This optimized method has also been applied to other mammalian species, 
such as pigs, sheep and monkeys (Hai et al., 2014, Hongbing et al., 2014, Wan et al., 
2015). This strategy will be used to accelerate the generation of suitable animal 
models for various disease studies.  
One of the most promising applications of CRISPR/Cas9 technology is the disruption 
of virus infection of the host. Currently, the largest challenge in clearing human 
immunodeficiency virus (HIV) in humans is the removal of the latently integrated viral 
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genome from reservoir cells (Churchill et al., 2016). Recent promising studies have 
shown that the CRISPR/Cas9 system can be used to efficiently remove integrated HIV 
DNA from infected CD4+ T cells (in vitro) with undetectable off-target mutations (Hu 
et al., 2014, Guo et al., 2015, Li et al., 2015, Zhu et al., 2015). The CD4+ T cells that 
co-expressed Cas9 and gRNA can also protect cells from subsequent infection (Liao 
et al., 2015a, Kaminski et al., 2015). Furthermore, the CRISPR/Cas9 system has been 
proven to inhibit HIV replication in ex vivo cultures of CD4+ T cells taken from clinical 
samples infected with HIV (Kaminski et al., 2016). These studies indicate the 
CRISPR/Cas9 system could be used as a novel therapeutic strategy for curing HIV 
infection. Clearance of hepatitis B virus (HBV) infection is also complicated by 
persistence of episomal DNA in the host (covalently closed circular DNA- cccDNA) 
(Levrero et al., 2009).  HBV replication has been significantly inhibited when infected 
cells have been transfected with CRISRP/Cas9 plasmids targeting viral cccDNA 
(Ramanan et al., 2015, Kennedy et al., 2015, Dong et al., 2015). In a recombinant 
cccDNA mouse model, a lentivirus-delivered CRISPR/Cas9 cassette decreased viral 
loads in vivo (Lin et al., 2014). The recent discovery indicating the CRISPR/Ca9 
system can target RNA sequences will further expand its potential antiviral 
applications (Price et al., 2015). 
There are however, some important limitations of the CRISPR/Cas9 system that need 
to be discussed. The first involves PAM-dependent target identification. However, 
different PAMs are required to facilitate endonuclease activity of Cas9 proteins 
isolated from different species, such as PAM of NGG for Streptococcus pyogenes and 
PAM of NNAGAAW (W = A or T) for Streptococcus thermophiles (Horvath and 
Barrangou, 2010). While these PAM sequences can be found in the mammalian 
genome as often as every 8–12 bp (Hsu et al., 2013, Cong et al., 2013), rare targets 
could be hindered by this PAM requirement. Moreover, Cas9s from different bacteria 
strains have also been engineered, such as Cas9 from Neisseria meningitides 
(NmCas9) (Hou et al., 2013). NmCas9 is characterized by a 24-bp-length recognition 
domain sequence and unique PAM motif (NNNNGATT or NNNNGCTT), which confers 
a higher specificity over previous 20-bp-length spacers. Most recently, a novel 
CRISPR enzymes, termed Cpf1, were discovered from Acidaminococcus and 
Lachnospiraceae species that can modify the human genome (Zetsche et al., 2015). 
Cpf1 enzymes use a different PAM sequence (TTN) instead of NGG for Cas9 protein 
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(Zetsche et al., 2015). With the emergence of these novel CRISPR-related enzymes, 
the PAM requirement can be offset by selecting different CRISPR enzymes in the 
future.  
Another limitation of the CRISPR/Cas9 system is the possibility of off-target 
mutagenesis. Previous studies have reported that the CRISPR/Cas9 system can 
tolerate up to five mismatches in crRNA (Fu et al., 2013). The frequency of off-target 
effects is related to the amount of transfected plasmids, as well as the ratios of Cas9 
and gRNA (Hsu et al., 2013, Ran et al., 2013b). It is therefore highly recommended 
that plasmids for transfection are titrated and optimized Cas9 and gRNA ratios used 
according to target and cell type. Another strategy to minimize off-target mutagenesis 
is using a D10A mutant Cas9 nickase (Cas9n), which can only cleave one strand of 
DNA (Mali et al., 2013a, Ran et al., 2013a). In this method, pairs of gRNAs are 
transfected into cells to introduce single-stranded nicks on both strands of target loci 
to form DSBs. When the off-target event happened in other sites, single nick can be 
repaired by DNA repair programs without producing mutation. This method can 
increase the specificity of the CRISPR/Cas9 system without reducing its efficiency.  
1.4.4 Evaluation of three genome-editing tools 
ZFNs, TALENs and CRISPR/Cas9 are revolutionary tools for biological research and 
therapeutic development. A brief comparison among ZFNs, TALENs and 
CRISPR/Cas9 is shown in Table 1. The full utilization of these technologies will 
depend on finding solutions to the following issues. Firstly, considerable improvements 
still need to be made on the specificity of engineered nucleases to reduce the 
frequency of off-target mutagenesis. Secondly, more rapid and effective methods 
need to be developed to monitor off-target events. For ZFNs and TALENs, an 
improved delivery system, particularly in vivo, will be essential for their further 
application in gene therapies (Perez-Pinera et al., 2012).  
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Table 1.1. A brief comparison of ZFN, TALEN and CRISPR/Cas9 
 ZFN TALEN CRISPR/Cas9 
Target-binding principle Protein-DNA 
specific recognition 
Protein-DNA 
specific recognition 
Watson Crick 
complementary 
rule 
Mechanisms ZFN specifically 
recognizes the 
target DNA 
and dimeric Fok I 
makes the DSB, 
which is 
repaired by NHEJ 
or HR 
TALE specifically 
recognizes the 
target DNA 
and dimeric Fok I 
makes the DSB, 
which is 
repaired by NHEJ 
or HR 
Guide RNA 
specifically 
recognizes the 
target 
DNA and Cas9 
makes the DSB, 
which is 
repaired by NHEJ 
or HR 
Essential components ZFN-Fok I fusion 
protein 
TALE-Fok I fusion 
protein 
gRNA and Cas9 
Efficiency High but variable High but variable High but variable 
Off-target effects Minor effects Minor effects Not determined 
Target site availability No restriction No restriction PAM (NGG) motif 
restriction 
Work in pair/dimmer  Yes Yes No 
Inheritability in animals Yes Yes Not determined 
3D structure Yes Yes Yes 
Time required 
for construction 
7-10 days 5-7 days 1-3 days 
Multiplex targeting Not determined Not determined Yes 
Target DNA length 2 x 9 bp + spacer 
(14-18 bp) 
2 x 17 bp + spacer 
(14-18 bp) 
20 bp 
Designed component Protein Protein RNA 
Origin of discovery Plant pathogen Plant pathogen E. coli 
 
1.5 Transgenic chickens 
Transgenic animals were first generated in 1981 through integration of exogenous 
DNA into mouse germ lines (Gordon and Ruddle, 1981). Eight years later, the first 
transgenic chicken line was generated using an avian retrovirus (Salter and Crittenden, 
1989). However, since then, the development of additional transgenic chickens has 
lagged behind other mammalian species as a result of its unique embryo development. 
Lack of a one-cell stage in the egg is an obvious obstacle for the generation of 
transgenic chickens as it hinders many technologies already used for mammalian 
species, i.e zygote injection (Nishijima and Iijima, 2013). Another factor is that the 
chicken genome is less defined and characterized than other species. Novel 
technologies, such as high-throughput sequencing and new genome editing tools, 
		
	
24	
have enabled the generation of new transgenic chickens, which will be discussed 
below. 
1.5.1 The chicken genome 
The chicken genome was sequenced in 2004 by the International Chicken Genome 
Sequencing Consortium (Hillier et al., 2004). The genome comprises approximately 
one billion base pairs of sequence, and provides resources (such as cDNA, BAC 
clones and genetic markers) and information for further research (Antin and Konieczka, 
2005). The first part of the chicken genome to be assembled was that encoding the 
major histocompatibility complex (MHC) (Kaufman et al., 1999). Large-scale analyses 
have uncovered a list of chicken cytokines, chemokines and their receptors, including 
23 interleukins, 8 type I interferons, 1 colony-stimulating factor (GM-CSF), 2 of the 3 
known transforming growth factors (TGFs), 24 chemokines (one C chemokine (XCL), 
14 C-C chemokines (CCL), 8 CXC chemokine ligands (CXCL) and 1 CX3C chemokine 
(CX3CL)) and 10 tumor necrosis factor superfamily (TNFSF) members (Hillier et al., 
2004, Kaiser et al., 2004a, Kaiser et al., 2005, Wang et al., 2005). Orthologous genes 
in the mammalian immune system have also been identified in the chicken genome, 
although there are key chemokine genes missing, including CCL2, 7, 8, 11, 15, 18, 23, 
24 and 26, and CXCL1–7, 9, 10 and 11 (Hillier et al., 2004).  
1.5.2 Generation of transgenic chickens 
Many approaches have been developed to manipulate the chicken genome with the 
aim of improving disease resistance or meat and egg productivity. Attempts have been 
made to generate transgenic chickens using viral vectors, such as retroviruses or 
lentiviruses to transfect blastodermal cells at early embryonic stages [stage 13-14 
Hamburger and Hamilton(HH)] (Harvey et al., 2002b, Mcgrew et al., 2004, Kamihira 
et al., 2005, Scott and Lois, 2006, Lillico et al., 2007, Zhang et al., 2012). However, 
transgenic chickens generated using these methods do not comply with food safety 
and biosafety regulations. As such, non-viral methods have been preferred. 
Transgenesis of chicken primordial germ cells (PGCs) is one successful example. 
PGCs are the precursors of sperm and oocytes that move through the blood stream 
in birds but not in mammals (Chang et al., 1992, Naito et al., 1999). This feature allows 
the isolation, transfection or replacement of PGCs in chickens. Several groups have 
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successfully developed transgenic chickens that express GFP using piggybac and/or 
Tol2 transposons by modifying PGCs in vitro or in vivo (Macdonald et al., 2012, Park 
and Han, 2012, Tyack et al., 2013). Notably, the strategy developed by the 
Commonwealth Scientific and Industrial Research Organization (CSIRO) is simple 
and rapid, and involves direct transfection of PGCs at stage 14 HH in vivo using 
miniTol2 transposon plasmids. This method has the advantage of avoiding technically 
demanding and labor-intensive tasks such as culturing PGCs in vitro (Tyack et al., 
2013). However, the mechanism of transposon integration involves random insertion 
of a foreign gene (i.e. GFP) into the chicken genome and thus cannot be used to target 
specific genes of interest. 
The first gene-specific knockout chicken was produced in 2013 using homologous 
recombination (Schusser et al., 2013). A sophisticated target vector was designed 
consisting of two homologous arms, a GFP gene under control of a β-actin promoter 
and a puromycin-resistant gene under control of a CAGGS promoter. The target vector 
was transfected into in vitro-cultured PGCs to replace the jointing gene segment of the 
chicken immunoglobulin heavy chain. Through puromycin selection, modified PGCs 
were isolated at a frequency of 1 in 107. Using these modified PGCs, a homozygous 
knockout chicken was generated with the loss of B cell production. This was followed 
by the generation of a chicken line lacking ovalbumin using TALENs (Park et al., 2014). 
In this study, PGCs were modified using TALENs and transplanted into recipient 
chicken embryos. The monoallelic mutant chicks were produced through germline 
transmission. The TALEN technology significantly increased the proportion of modified 
PGCs in transfected cells when compared to homologous recombination. However, 
the low number of additional gene-specific knockout chickens generated since these 
two studies were published indicates that the current technology is still inefficient and 
technically demanding. 
1.5.3 Use of transgenic chickens 
Chickens have been used to study fundamental biology for more than 100 years with 
the discovery of B cells and tumor viruses as key examples (Brown et al., 2003). 
Moreover, chicken embryos were used to study early development of the 
cardiovascular system (Galper and Catterall, 1978). The accessibility of the chicken 
embryo  allows real-time analysis of development in vivo (De Melo Bernardo et al., 
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2015). The chicken, as a domestic animal, is not only a source of meat and egg 
production for humans, but also a host for zoonotic pathogens, such as Salmonella 
enteritidis (chenHenzler et al., 1994) and influenza viruses (Alexander, 2007). As such, 
it is important use chickens as a relevant animal models to study host-pathogen 
interactions. 
Transgenic chickens have also been used as “bioactor” through the production of 
exogenous proteins in eggs. Foreign genes can be inserted into chicken yolk-proteins 
or albumen-proteins to express foreign proteins of interest. The most successful 
application of transgenic chickens as ‘bioactors’ is the production of KANUMATM, 
a hydrolytic lysosomal cholesteryl ester and triacylglycerol-specific enzyme, (Alexion 
Pharmaceuticals), approved by the US Food and Drug Administration (FDA) for the 
treatment of Lysosomal Acid Lipase (LAL) deficiency (Sheridan, 2016). Compared 
with the traditional protein expression systems, eggs are thought to be low cost and 
give high yields.  
Another potential use for transgenic chickens is propagation of disease-resistant lines. 
The avian leukosis virus (ALV) envelop glycoprotein gene was integrated into the 
chicken genome in an attempt to generate chickens resistant to infection (Salter and 
Crittenden, 1989). Unfortunately, the transgenic chicken exhibited only partial 
protection to infection and was prone to oncogenesis. With the introduction of RNA 
interference, a transgenic chicken line was generated expressing a short-hairpin RNA 
to inhibit influenza virus replication (Lyall and Tiley, 2011). Although the transgenic 
chickens were resistant to virus transmission, they succumbed to influenza virus 
infection. As new technologies emerge, an alternative strategy may be to knockout 
virus receptors in chickens to prevent infection. However, potential side effects of this 
receptor-knockout chicken should be considered carefully given the essential 
functions these proteins perform. Further studies are required to identify appropriate 
targets for the generation of disease-resistant chickens. 
As an important source of food, improving production traits of chickens is likely to 
interest the commercial poultry industry. Many hormones and growth factors involved 
in chicken growth have already been described (Sharp, 1993). With the advent of 
genome editing technologies, development of ‘muscular chickens’ may be possible 
through manipulation of genes associated with muscle growth, such as myostatin. 
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Myostatin, also known as growth differentiation factor 8, inhibits muscle cell growth 
and differentiation (Bellinge et al., 2005). Animals that carry a naturally occurring 
mutation in the myostatin gene have increased muscle mass than those with the wild 
type gene. By targeting the myostatin gene, transgenic sheep, cattle and pigs have 
been successfully generated that show increased muscle mass (McPherron and Lee, 
1997, Wang et al., 2015b, Qian et al., 2015).  
1.6 Project Hypothesis  
CRISPR/Cas9 technology has been successfully applied in a number of animal 
models. We hypothesize that CRISPR/Cas9 technology can be used to efficiently 
modify the chicken genome to reduce/eliminate expression of ChIL-6, a cytokine 
associated with pathogenicity in chickens following influenza virus infection.  
 
1.7 Project Aims 
1):	To validate CRISPR/Cas9 plasmids in chicken DF1 and HD11 cell lines.		
2): To identify a role for ChIL-6 in influenza virus infection using knockout cell lines.		
3): To generate ChIL6-knockout chicken PGCs for future generation of knockout 
chickens.	
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Chapter 2   Materials and Methods 
 
2.1 General method 
2.1.1 Cell culture 
All cell lines were provided by the tissue culture facility at the Australian Animal Health 
Laboratory (AAHL), CSIRO.  
Chicken DF-1 embryo fibroblast cells and HD11 macrophage-like cells were 
maintained in (DMEM) (Gibco, USA), supplemented with 10% foetal calf serum (FCS) 
(FisherBiotec, Australia), 100 U/mL penicillin and 100 µg/mL streptomycin (Gibco, 
USA), and cultured at 37°C, 5% CO2. These cells were passaged twice a week. The 
cells were infected with influenza virus between passages 5 and 10.  
The murine hybridoma cell line 7TD1 was maintained in DMEM media, supplemented 
with 10% FCS, 0.55 mM arginine (Sigma-Aldrich, Germany), 0.24 mM asparagine 
(Sigma-Aldrich, Germany) and 0.5 ng/mL recombinant chicken interleukin-6 (ChIL-6) 
(Abcam, USA), and maintained at 37°C, 5% CO2. Madin–Darby Canine Kidney 
(MDCK) cells (ATCC, CCL-34) were maintained in Roswell Park Memorial Institute 
(RPMI) (Invitrogen, USA) medium supplemented with 10% FCS, 2 mM L-glutamine, 
1.5% sodium bicarbonate, 100 U/mL penicillin and 100 µg/mL streptomycin. 
Chicken primordial germ cells (PGCs) were cultured and maintained at 37°C, 5% CO2 
as previously described (Van de Lavoir et al., 2006). Briefly, PGCs were maintained 
in knockout DMEM supplemented with 7.5% FCS, 2.5% chicken serum (Sigma-Aldrich, 
Germany), 1× antibiotic–antimycotic (100 units/mL of penicillin, 100 µg/mL of 
streptomycin, and 0.25 µg/mL of Gibco Amphotericin B) (Gibco, USA), 2 mM Glutamax 
(Gibco, USA), 0.1 mM 2-mercaptoethanol (Gibco, USA), 1× glutamine synthetase 
expression medium (GSEM) supplement (catalogue number G9785, Sigma-Aldrich, 
Germany), mouse stem cell factor (6 ng/mL) (Peprotech, Israel) and human basic 
fibroblast growth factor (4 ng/mL) (Peprotech, Israel). PGCs were seeded onto a 
monolayer of irradiated mouse embryonic fibroblast feeder cells and subcultured every 
seven days.  
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Green fluorescent protein (GFP)-positive PGCs and GFP-positive DF1 cells used in 
Chapter 5 were gifts from Dr. Timothy Doran (CSIRO, Australian Animal Health 
Laboratory) and were generated using the published Tol2 construction method (Tyack 
et al., 2013). Briefly, the Tol2 plasmid system requires two plasmids; one plasmid 
contains an enhanced GFP (EGFP) gene flanked by the Tol2 sequence (termed 
pMiniTol-EGFP) and the second plasmid expresses transposase (designated pTrans). 
To transfect 3 × 106 PGC or DF1 cells, 1 µg of pMiniTol-EGFP and 2 μg of pTrans 
were mixed with 10 μL of lipofectamine 2000 transfection reagent according to the 
manufacturer’s instructions (Life Technologies, USA). At third week post-transfection, 
cells stably expressing GFP were bulk or individually sorted using flow cytometry and 
expanded for subsequent experiments. 
2.1.2 Primers and oligonucleotides  
PCR primers were designed using the NCBI primer designing tool 
(http://www.ncbi.nlm.nih.gov/tools/primer-blast/) and were purchased from 
GeneWorks (Australia). Primers were resuspended in nuclease-free water to a final 
concentration of 100 μM and were further diluted to a 5 μM working concentration. All 
the primers used are listed in Table 2.2. 
2.1.3 DNA and RNA extraction 
Genomic DNA was extracted from cells using DNeasy Blood & Tissue Kits (Qiagen, 
Netherlands) following the manufacturer’s instructions. RNA was extracted from cells 
using RNeasy Mini Kits according to the manufacturer’s instructions (Qiagen, 
Netherlands). The concentrations of DNA and RNA were measured using a 
spectrophotometer (NanoDrop ND-1000 3.3 Spectrophotometer, NanoDrop 
Technologies, USA).  
2.1.4 Complementary DNA (cDNA) synthesis 
cDNA was prepared from RNA using SuperScript III first-strand synthesis SuperMix 
(Invitrogen, USA) according to the manufacturer’s instructions. Briefly, the reagents 
were combined in a tube as follows: 1 μL of random hexamers, 1 μL of annealing 
buffer, 2 μg of RNA and nuclease-free water up to 8 μL final volume. The mixture was 
then incubated in a thermal cycler at 65°C for 5 min, and then cooled on ice for at least 
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1 min. Subsequently, 10 μL of First-Strand Reaction Mix and 2 μL of 
SuperScriptIII/RNase Enzyme Mix was added to the mixture. The reaction was 
initiated by placing samples at 25°C for 10 min followed by 50 min at 50°C, terminated 
at 85°C for 5 min and then stored at -20°C for future analysis. 
2.1.5 PCR amplification 
The two types of polymerase used in this study were Gotaq polymerase (Promega, 
USA) and high-fidelity Phusion polymerase (Thermo, USA). High-fidelity Phusion 
polymerase was used to amplify fragments for construction of vectors. In all other 
cases, Gotaq polymerase was used. The polymerase chain reaction (PCR) was 
performed following the manufacturer’s instructions. For Gotaq polymerase, the 
components of the reaction were: 4 μL of buffer, 1.2 μL of MgCl2 (25 mM), 2 μL of 
forward primer (5 μM), 2 μL of reverse primer (5 μM), 0.5 μL of dNTP (10 mM), 0.2 μL 
of Gotaq polymerase (5u/μL), 2 μL of sample DNA and 8 μL of water to a final 20 μL 
volume. The PCR conditions were: an initial denaturation step at 94°C for 5 min 
followed by 35 cycles of denaturation at 94°C for 30 s; annealing at temperatures 
calculated for various primers for 30 s; elongation at 72°C was time dependent based 
on the length of the PCR product; and finally one cycle of post-elongation at 72°C for 
10 min. For Phusion polymerase, the reagents were: 10 μL of master mix, 2 μL of 
forward primer (5 μM), 2 μL of reverse primer (5 μM), 2 μL of sample DNA and 8 μL 
of water to a final 20 μL volume. The PCR conditions started with an initial denaturation 
at 98°C for 30s followed by 35 cycles of denaturation at 98°C for 2s; annealing at 
temperatures calculated for various primers for 5s; elongation at 72°C was time 
dependent based on the length of the PCR product; and then one cycle of post-
elongation at 72°C for 5 min. The PCR amplification was performed using an 
Eppendorf Mastercycler ep Gradient S (Eppendorf, USA) thermal cycler machine. To 
overcome the difficulty of amplifying high GC content regions in ChIL-6 gene, 10% 
dimethyl sulfoxide (DMSO) was added to some reactions. 
2.1.6 Gel electrophoresis, DNA extraction and ligation 
PCR products were visualized by agarose gel electrophoresis (Promega, USA) 
containing 0.01% (V/V) GelRred stain (Not from Invitrogen. Check). The size of PCR 
products was estimated according to the 1 Kb Plus DNA Ladder (Invitrogen, USA). 
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DNA bands of the expected size were cut from the gel and extracted using a QIAquick 
gel extraction kit (Qiagen, Netherlands) according to the manufacturer’s instructions. 
The concentration of DNA was measured using a NanoDrop spectrophotometer. The 
purified DNA was ligated into a pGEM-T vector (Promega, USA) following the 
manufacturer’s instructions and prepared for sequencing. Briefly, 200 ng DNA sample 
was mixed with 1 μL of T4 DNA ligase (Promega, USA), 10 μL of ligase buffer (2× 
stock), 1 μL of pGEM-T vector (50 ng/μL) and nuclease-free water to a 20 μL final 
volume. The reaction was incubated at room temperature (25°C) for 1 h or 4°C 
overnight. 
2.1.7 Transformation 
The ligation product was transformed into JM109 (Promega, USA) or DH5a (Invitrogen, 
USA) competent cells according to the manufacturers’ instructions. Briefly, 5 μL of 
ligation product was added into 25 μL of ice-cold competent cells and incubated on 
ice for 30 min. Cells were then heat-shocked at 42°C for 30 s and immediately 
incubated on ice for 2 min. One hundred μL of Luria Bertani (LB) broth medium was 
added to competent cells and spread onto LB agar plates containing antibiotics based 
on the antibiotic resistance incorporated into different plasmids. The agar plates were 
incubated at 37°C overnight.  
2.1.8 Clone selection 
Colony growth on agar plates was inspected on the second day after transformation. 
Five colonies on each plate were selected for miniprep analysis using the Plasmid 
Miniprep Kit (Qiagen). Specific primers on the plasmids were used to amplify the 
region of interest and positive colonies were confirmed by sequencing analysis or 
agarose gel electrophoresis. Positive colonies were placed in 5 mL of LB broth 
containing appropriate antibiotics (100 ug/mL) and cultured at 37°C overnight. 
2.1.9 Plasmid purification 
Plasmid DNA was isolated from culture using a QIAprep Spin Miniprep Kit (Qiagen, 
Netherlands) according to the manufacturer's instructions to isolate a large amount of 
plasmid DNA. The concentration of plasmid DNA was measured using a NanoDrop 
spectrophotometer. 
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2.1.10 Sequencing 
Sequencing reactions were performed using a BigDye Terminator v3.1 cycle 
sequencing kit (ThermoFisher, USA) according to the manufacturer’s instructions. 
Briefly, to 300 ng of purified plasmid DNA the following was added: 1 μL of Big-Dye 
terminator premix, 4 μL of 5× buffer, 1 μL of primer (5 mM) and nuclease-free water to 
a final 20 μL volume. Thermal cycling conditions involved an initial denaturation step 
at 96°C for 1 min followed by 30 cycles of denaturation at 96°C for 10 s; annealing at 
50°C for 5 s; then elongation at 60°C for 4 min. Sequencing analysis was performed 
using online software (http://blast.ncbi.nlm.nih.gov/Blast.cgi). 
2.1.11 Microscopy 
To check growth of the continuous cell lines, cells were routinely observed under a 
bright-field microscope (Leica, Germany). For GFP-positive cell lines, cells were 
observed under a fluorescent microscope (Leica, Germany) using an excitation 
(470/440) and emission filter (525/50). Images were taken at 10×, 20× or 40× 
magnification. 
2.2 Generation of DF1 and HD11 IL-6-/- cell lines 
2.2.1 Plasmid construction 
Expression plasmids containing gRNA that target exon 2 of ChIL-6 (target 1, IL-6-
gRNA-1) were constructed following Church’s lab protocol (Mali et al., 2013b). The 
CRISPR target was designed using ZiFiT (http://zifit.partners.org/ZiFiT/). 
Subsequently, a pair of oligonucleotides were annealed and extended using Phusion 
polymerase to generate a 100-nt dsDNA insert fragment containing the target 
sequence. The dsDNA fragment was purified and incorporated into a gRNA cloning 
vector (Addgene # 41824) at the AfIII restriction site using the Gibson assembly (NEB, 
USA). The constructed plasmids were then confirmed by sequencing. 
2.2.2 The generation of homologous directed repair (HDR) template  
To facilitate the isolation of modified cells, an HDR template containing a GFP 
expression cassette was generated as shown in Figure 2.1. A 341-bp region of the 
ChIL-6 locus containing the target site was amplified by PCR from a chicken genomic 
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DNA template using the primer pair IL-6-UP-F and IL-6-DW-R. The left arm was then 
amplified using the primer pair IL-6-UP-F and IL-6-UP-R. There is a 5¢ overhang 
complementary to the 3¢ end of the GFP molecule on this reverse primer. The right 
arm was amplified using primers IL-6-DW-F and IL-6-DW-R. There is a 5¢ overhang 
complementary to the 5¢ end of the GFP molecule on this forward primer. The GFP 
expression cassette, containing a CMV promoter, an EGFP gene and a SV40 polyA 
tail, was amplified from pEGFP-N1 plasmids using two primers (GFP-F and GFP-R) 
that have a 5¢ overhang complementary to the 5¢ and 3¢ ends of the ChIL-6 
homologous arms, respectively. The left and right ChIL-6 homologous arms and GFP 
cassette fragment were then mixed together at a 1:1:1 ratio and served as a template 
for an overlap extension PCR using the IL-6-UP-F and IL-6-DW-R primer pair to 
generate a linear HDR template. To optimize the generation of modified PGCs, long-
arm HDRs were generated. The generation method was similar to the 
abovementioned process, but included different primers (listed in Table 2.2).  
 
Figure 2.1. Illustration diagram of the generation of HDR. The target area is labelled in red. Blue 
indicates the overlapping sequences of primers used for the generation of the HDR template. 
2.2.3 Transfection and purification 
DF1 cells were seeded at 1.0 × 106 cells per well in a six-well plate for 24 hours (hrs) 
prior to transfection. The cells were then co-transfected with 1 μg of IL-6-gRNA-1 
plasmid, 1 μg of hCas9 plasmid and 1 μg of HDR templates using Lipofectamine 2000 
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(Life technologies, USA). Fourteen days after transfection, GFP-positive DF1 cells 
were sorted into 96-well tissue culture plates at one cell per well using fluorescence 
activated cell sorting (FACS). A pair of primers (GFP-test-F and GFP-test-R) were 
designed to detect the precise integration of the GFP in the ChIL-6 gene. 
2.2.4 Western blot 
Infected wild-type (WT) and chicken IL-6 knockout (ChIL-6-/-) cells (DF1 and HD11) 
were lysed using RIPA buffer (Roche, Switzerland). The amount of protein was 
detected using a spectrophotometer (NanoDrop, USA). Pre-treated proteins were 
loaded onto SDS-PAGE in equal amounts and then transferred to polyvinylidene 
difluoride membranes (Bio-Rad, USA). Membranes were probed with rabbit polyclonal 
antibodies against ChIL-6 (AbD Serotec, USA) at a dilution of 1:1000 and incubated 
at 4°C overnight. On the second day, membranes were washed three times for 10 min 
with PBST and incubated with horseradish peroxidase (HRP)-conjugated goat anti-
rabbit IgG secondary antibody (Life Technologies, USA). After 1 h incubation, 
membranes were again washed three times for 10 min with PBST. Membranes were 
then exposed to Pierce ECL Plus Western blotting substrate (Thermo Scientific, USA), 
to visualize protein bands. Protein band density was quantified using ImageLab™ 
software (Bio-Rad, USA).   
2.2.5 7TD1 assay 
To test whether ChIL-6 functionality was disrupted by the disruption of the ChIL-6 gene, 
WT and ChIL-6-/-  cells were stimulated with LPS (1 ng/mL, Sigma-Aldrich, Germany) 
for 24 hrs and supernatants were harvested and concentrated using Amicon Ultra-15 
Centrifugal Filter Units (Millipore, Germany). 7TD1 cells were cultured in DMEM 
supplemented with recombinant ChIL-6 (Abcam, 0.5 ng/mL) for three days. The 
residual ChIL-6 in the cells was removed by three washes in DMEM, and the cells 
cultured for three days in medium without ChIL-6. Recombinant ChIL-6 protein was 
serially diluted from 10 ng/mL to 10–5 ng/mL in opaque-walled 96-well tissue culture 
plates to generate a standard curve. Concentrated supernatant obtained from LPS 
stimulation were added into 96-well plates, along with 1,500 serum-starved 7TD1 cells 
and plates incubated at 37°C in a humidified CO2 incubator for 72 hrs. The density of 
7TD1 cells is associated with the concentration of ChIL-6 in the supernatant and this 
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was determined using luminescence signal following the addition of CellTiter-GloR 2.0 
Reagent (Promega, USA) according to manufacturer’s instructions. Luminescence 
signal was recorded using a Synergy HT plate reader (Biotek, USA) and the 
concentration of ChIL-6 in the supernatant was calculated using the standard curve. 
2.3 Characterization of ChIL-6-/- cell lines with influenza virus 
infection 
2.3.1 Influenza A Viruses 
A/Puerto Rico/8/1934 H1N1 (PR8) virus was obtained from The University of 
Melbourne, Australia. The HPAI A/chicken/Vietnam/0008/2004 H5N1 (H5N1) virus 
was obtained from CSIRO AAHL. Virus stock was prepared using standard methods 
in 10-day-old embryonated eggs. H5N1 experiments were performed in biosafety level 
3 laboratories (BSL3) at CSIRO AAHL. 
2.3.2 Virus infection  
Cells were infected with influenza A virus at multiplicities of infection (MOI) of 0.01 or 
1 as previously described (Ye et al., 2015). Briefly, cells were prepared in 6- or 12-well 
plates one day before infection. Confluent cells were washed three times and 
inoculated at various MOIs. After 1 h of incubation at 37°C, inoculums were removed 
from wells by washing with PBS and 1 mL of OPTI-MEM media (Invitrogen, USA) 
containing100 U/mL penicillin and 100 µg/mL streptomycin was added into the wells. 
Supernatant was collected at 24h post infection to measure virus titers. Cell lysis was 
performed to extract RNA for further analysis. 
2.3.3 Plaque assay 
To measure influenza virus titers, plaque assay experiments were performed on a 
MDCK cell monolayer as described previously (Zeng et al., 2007). MDCK cell 
monolayers was seeded on six-well plates and incubated overnight. In duplicates, 150 
μL of serial 10-fold dilutions (10–1–10–7) of supernatant collected from infected cells 
was added onto monolayers. The plates were then incubated at 37°C for 45 min and 
shaken gently every 15 min. After absorption, 3 mL of agar overlay was added to each 
well, which consisted of 0.9% agarose gel (Sigma-Aldrich, Germany), 0.5 mg/mL 
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trypsin Worthington (Sigma-Aldrich, Germany) and 1× L15 media (Invitrogen, USA). 
The plates were then incubated at 37°C for 3 days in a 5% CO2 incubator. Plaque-
forming units in each well were counted after 1% crystal violet staining. 
2.3.4 Quantitative real-time reverse transcriptase PCR (qRT-PCR) 
DF1 and HD11 cell lysates from influenza virus-infected cells were collected at 24h 
post infection and RNA extraction performed using an RNeasy mini kit (Qiagen, 
Netherlands) following the manufacturer's instructions. cDNA was then synthesized 
using SuperScript III first-strand synthesis SuperMix (noted in 2.1.4). The expression 
levels of mRNA of interest was determined by TaqMan gene expression assays 
(Applied Biosystems, USA) using commercial TaqMan primers and probes, and 
custom-made chicken β-actin (forward primer, 5¢-TGCGTGACATCAAGGAGAAG-3¢; 
reverse primer, 5¢-GACCATCAGGGAGTTCATAGC-3¢; probe, 5¢-FAM-
TGTGCTACGTCGCACTGGATTTCGA-NFQ-3¢) and ChIL-6 gene (forward primer, 5¢- 
CAAGGTGACGGAGGAGGA-3¢; reverse primer, 5¢-GAGAGCTTCGTCAGGCATTT-
3¢; probe, 5¢-FAM-CTGCCTGCTCGCCGGCTT-NFQ-3¢). The PCRs were performed 
under the following conditions: samples were placed at 50°C for 2 min and 95°C for 
10 min followed by 40 cycles of 95°C for 15 s and 60°C for 1 min. The comparative 
threshold (CT) value of the target gene was normalized to β-actin mRNA CT values 
and fold changes were calculated using the 2–ΔΔCT method relative to the control group.  
2.3.5 Cell proliferation assay 
DF1 and HD11 cells (1.0 × 104) were placed into 96 opaque-walled well plates. Cell 
numbers were calculated daily using the CellTiter-Glo Luminescent Cell Viability 
Assay Kit (Promega, USA) according to manufacturer’s instructions. Briefly, cell and 
CellTiter-Glo reagent were equilibrated at room temperature for 30 min. To lyse cells, 
50μl of CellTiter-Glo reagent was added into each well and mixed for 2 min on a shaker. 
The plate was incubated at room temperature for a further 10 min to stabilize 
luminescent signal. Fluorescence in each well was recorded using a Synergy HT plate 
reader.  
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2.3.6 Detection of reactive oxygen species (ROS) and immunofluorescent 
staining 
Monolayers of DF1 and HD11 cells were seeded in 96-well plates and were infected 
with PR8 virus at a MOI of 1. At 24 hrs post-infection, ROS production in infected or 
uninfected cells was measured using CellROX Deep Red reagent (Thermo, USA). 
Briefly, 5μM CellROX reagent was added into cells and incubated for 30 min at 37°C. 
The cells were then fixed with 4% Paraformaldehyde and nuclei stained with DAPI 
(4′,6′-diamidino-2-phenylindole). ROS and DAPI fluorescence was scanned and 
quantified using a CellInsight Personal Cell Imager (Thermo, USA). The average ROS 
fluorescence per cell was analyzed using Cellnsight software (Thermo, USA).  
2.3.7 Caspase-3/7 Activation Assays 
DF1 and HD11 cells were placed in 96-well plates and infected with PR8 virus at a 
MOI of 10 or 1. Caspase-3/7 activation in infected and non-infected cells was 
measured using the Caspase-Glo 3/7 Assay Kit (Promega, USA) following the 
manufacturer’s instructions. Briefly, 50 μL Caspase-Glo 3/7 reagent was added into 
each well in a 96-well plate and incubated for 1 h. The fluorescence of each well was 
measured using a Synergy HT plate reader. 
2.3.8 Rescue of ChIL-6-/- phenotype 
To rescue the ChIL6-/- phenotype, HD11 WT and ChIL-6-/- cells were initially infected 
with PR8 virus as described in section 2.3.2. At the same time as infection, 
recombinant ChIL-6 was added into culture at a final concentration of 1ng/mL. After 
24h, supernatants were collected for plaque assay analysis as described in section 
2.3.3. 
2.3.9 Statistical analysis 
Data are presented as means ± standard deviations (SD) and were calculated using 
Excel (Microsoft, USA). Two-tailed student’s t-tests were used to determine 
differences between WT and ChIL-6-/- cell lines. Differences were considered 
statistically significant when the p values were <0.05. Statistical analyses were 
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performed using GraphPad Prism (v5.02) software (GraphPad Software, USA) for 
Windows. 
2.4 Generation of PGC knockout cell line 
2.4.1 Plasmid construction 
Two gRNAs that target exon 3 of ChIL-6 (IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3) 
were designed using an online tool (http://crispr.mit.edu/) and CRISPR/Cas9 plasmids 
were constructed using Zhang’s lab protocol (Ran et al., 2013b). Briefly, 20-nt oligo 
pairs (Table 2.2) were annealed and inserted into the pSpCas9(BB)-2A-Puro plasmid 
(Addgene #48139) using the BbsI restriction enzyme site. Correct gRNA-expressing 
plasmids were confirmed by sequencing. GFP-gRNA was provided as a gift from 
George Church (Addgene # 41820). All plasmids used in this study are listed in Table 
2.1; the primers used are listed in Table 2.2. 
2.4.2 Transfection and purification of PGCs 
GFP-positive chicken PGCs (1.0 × 106) were co-transfected with 1 μg of IL-6-gRNA-
Cas9-2, 1 μg of IL-6-gRNA-Cas9-3 and 1 μg of GFP-gRNA plasmids using 
Lipofectamine 2000 (Life Technologies, USA). GFP-negative PGCs were isolated by 
FACS 14 days after transfection, and genomic DNA extracted. A pair of primers, IL-6-
3F and IL-6-3R, were used to detect our target area to confirm ChIL-6 gene disruption. 
The PCR product was subjected to DNA agarose gel electrophoresis and analyzed 
using ImageLab™ software (Bio-Rad, USA). The percentage of PCR product 
corresponding to the proposed truncated ChIL-6 gene segment was then determined 
and sub-cloned into the pGEM-T vector for sequence analysis. 
2.4.3 Mutation detection 
A pair of primers (IL-6-3F and IL-6-3R) were designed to amplify the ChIL-6 gene 
containing two targets. A 549bp band was expected in the PCR product from the wild 
type ChIL-6 gene and a ~420bp band (the exact deletion of nucleotides cannot be 
predicted using the CRISPR/Cas system-detailed in Chapter 5.4) amplified from 
alleles targeted by the two gRNAs. The mutation ratio was calculated based on the 
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intensity of the ~420bp band and analyzed by ImageLab software. The ~420bp PCR 
fragment was then inserted into the pGEM-T vector for sequencing.  
2.4.4 Surveyor assay  
In our mutation detection assay, a ~500bp band was amplified in our PCR products 
located between the wild type band (549bp) and mutant band (~420bp). To determine 
whether this ~500bp band was caused by a mismatch between a WT allele and 
deleted allele, a Surveyor mutation detection assay was performed. The Surveyor 
nuclease is an specific enzyme  that cleaves mismatched bands and is widely used to 
detect mutation, deletion or insertion in genes (Qiu et al., 2004). A surveyor mutation 
detection kit (Thermo, USA) was used based on manufacturer’s instructions. Briefly, 
PCR products were subjected to a re-annealing program as follows; samples were 
placed at 95ºC for 10min, 95ºC to 85ºC with ramping at -2ºC/s, 85ºC to 25ºC, at -
0.25ºC/s, and a 25ºC hold for 1 min. The product was treated with Surveyor nuclease 
and Surveyor Enhancer S at 42ºC for 30 min visualized on 2% agarose following 
electrophoresis.  
2.5 Egg injection 
Egg injection is commonly used in the generation of transgenic chickens. Briefly, 
plasmids or PGCs are directly injected into the dorsal aorta of chicken embryos using 
a micropipette. The direct injection method established by Dr. Timothy Doran at the 
CSIRO Australia Animal Health Laboratory (AAHL) requires injection of Tol2 plasmids 
into chicken blood vessels to target circulating PGCs. This allows modified chicks to 
be selected in the next generation (Tyack et al., 2013). Apart from plasmids, in-vitro 
cultured PGCs can also be injected into recipient embryos and sperm from injected 
chicken is then collected to generate the transgenic chicks (Macdonald et al., 2012). 
2.5.1 Direct injection to test designed plasmids 
To test the plasmid constructs using a direct injection method, various plasmid 
combinations (listed in Table 2.3) were used to inject 14 Hamburger and Hamilton (HH) 
stage chicken embryos as described previously (Tyack et al., 2013).  Briefly, the 
plasmids were mixed with lipofectamine 2000 CD (chemical defined) and incubated 
for 30 min prior to injection. A small window was cut into the pointed end of the egg, 
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then 1–2 μL of transfection mixture was injected into the embryonic dorsal aorta using 
a micropipette. The eggs were sealed using paraffin film and hatched normally. At day 
7 or 14, the gonads were removed from chicken embryos to perform an imaging test 
or DNA extraction to detect gene mutations. 
2.5.2 Migration ability of modified PGCs to gonads 
To determine the migration ability of enriched, CRISPR-modified chicken PGCs, 
modified PGCs were transplanted into recipient chicken embryos using the direct 
injection method. Briefly, a small window was cut into the dorsal surface of the 2.5-
day-old recipient embryonated eggs. More than 5000 modified PGCs were 
microinjected into the recipient embryo using a micropipette and eggs were sealed 
with paraffin film. Chicken embryos were harvested at 7 days old and gonads were 
removed, pooled and digested with 0.25% trypsin for 7 min at 37°C. PGCs were then 
purified using a magnetic-activated cell sorting (MACS) purification column (Miltenyi 
Biotec, Germany) conjugated with chicken stage specific embryonic antigen 1 (SSEA-
1) antibody (a gift from the University of Iowa). PGCs attached to the column were 
collected and genomic DNA of purified PGCs was extracted and then analyzed by 
PCR using the primer pair IL-6-3F and IL-6-3R to detect ChIL-6 gene disruption. The 
PCR product was subjected to DNA agarose gel electrophoresis. The DNA gel was 
analyzed using ImageLab™ software and the percentage of PCR product 
corresponding to the truncated ChIL-6 gene segment was estimated. The PCR 
product was also sub-cloned into pGEM-T vector for sequencing analysis.  
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Table 2.1. List of plasmids used. 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
 
Plasmid	name	 Backbone	 Usage	
IL-6-gRNA-1	 gRNA_Cloning	Vector	 Expressing	gRNAs	targeting	exon2	of	ChIL-6	gene	
hCas9	plasmid	 hCas9	plasmid	 Expressing	Cas9	protein	
pEGFP-N1	 pEGFP-N1	 Used	to	amplify	the	GFP	expression	cassette	for	HDR	
GFP-gRNA	 gRNA_Cloning	Vector	 Expressing	gRNAs	targeting	GFP	gene	
IL-6-gRNA-Cas9-1	 pSpCas9(BB)-2A-puro	 Expressing	gRNAs	targeting	exon2	of	ChIL-6	gene	
IL-6-gRNA-Cas9-2	 pSpCas9(BB)-2A-Puro	 Expressing	Cas9	and	gRNA	targeting	exon3	of	ChIL-6	gene		
IL-6-gRNA-Cas9-3	 pSpCas9(BB)-2A-Puro	 Expressing	Cas9	and	gRNA	targeting	exon3	of	ChIL-6	gene		
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Table 2.2. List of primers used for gRNAs construction, HDR template construction and ChIL-6 
gene amplification. 
Primers	 Sequencing	(5’-3’)	
IL-6-gRNA-1-F	 TTTCTTGGCTTTATATATCTTGTGGAAAGGACGAAACACC	
GAGGACGGCTGCCTGCTCGC		
IL-6-gRNA-1-R	 GACTAGCCTTATTTTAACTTGCTATTTCTAGCTCTAAAAC	
GCGAGCAGGCAGCCGTCCTC	
IL-6-gRNA-Cas9-2-F	 CACCGGCCGCTGGAGAGCTTCGTC	
IL-6-gRNA-Cas9-2-R	 AAACGACGAAGCTCTCCAGCGGCC	
IL-6-gRNA-Cas9-3-F	 CACCGCAGATGGTGAGTCGGCGCG	
IL-6-gRNA-Cas9-3-R	 AAACCGCGCCGACTCACCATCTGC	
IL-6-UP-F	 CAGGACGAGGTGGGTACGG	
IL-6-UP-R	 GATTACTATTAATAACTATGTTCTCGCACACGGTGAA	
IL-6-DW-F	 TCATCAATGTATCTTAAGGGCCCAACCCGAGCGCCG	
IL-6-DW-R	 AGCTTCGTCAGGCATTTCTCC	
GFP-F	 GTTCACCGTGTGCGAGAACATAGTTATTAATAGTA	
GFP-R	 GGCGGCGCTCGGGTTGGGCCCTTAAGATACATTGA	
GFP-test-F		 GAGCAAAGACCCCAACGAGA	
GFP-test-R	 TTAGTCATAAGGGAAAGCAGCACAG	
HR-3.7kb-UF	 AGAATCCCTCAGCGAAAGGC	
HR-3.7kb-UR	 TGTTCTCGCACACGGTGAA	
HR-3.7kb-DF	 GGCCCAACCCGAGCGCCG	
HR-3.7kb-DR	 TTCCACACAAGGCCAGTCTC	
IL-6-3F		 TGCTGCTGACGTTCTCACTT	
IL-6-3R	 AAGCGAATCGGCCGTTGTAT	
Bold characters indicate the gRNA target sequences. Italic bold characters indicate the overlapping 
sequences for HDR template amplification for indicated genes. 
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Table 2.3. Plasmid combinations for direct injection 
Experimental   
group 
Plasmids used for direct injection Number of injected 
chicken embryos 
A IL-6-gRNA-1 (2µg) 
hCas9 (2µg) 
1.8kb HDR template (2µg) 
10 
B IL-6-gRNA-1 (2µg) 
hCas9 (2µg) 
4.0kb HDR template (2µg) 
10 
C IL-6-gRNA-Cas9-1 (2µg) 
1.8kb HDR template (2µg) 
10 
D IL-6-gRNA-Cas9-1 (2µg) 
4.0kb HDR template (2µg) 
10 
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Chapter 3    Generation of ChIL-6-/- DF1 and HD11 cells 
 
3.1 Introduction 
Precise gene editing technologies provide an unprecedented opportunity to illustrate 
the functionality of genes of interests through the generation of genetically modified 
animals. The most commonly used technologies include the use of engineered zinc-
finger nucleases (ZFNs), transcription activator-like effector nucleases (TALENs), and 
clustered regularly interspaced short palindromic repeats (CRISPR)/CRISPR 
associated (Cas) 9 (Gaj et al., 2013). The recognition of ZFNs and TALENs is based 
on protein-nucleotide binding involving an expression of a large protein (Urnov et al., 
2010, Boch et al., 2009), while the CRISPR/Cas9 system utilizes a RNA-DNA binding 
pattern to cleave double-stranded DNA (Jinek et al., 2013, Cho et al., 2013, Cong et 
al., 2013). Due to its simplicity, the CRISPR/Cas9 gene editing system is becoming 
the dominant tool in the field. 
The CRISPR/Cas9 system originated from the prokaryotic adaptive immune system. 
In bacterial genomes, a range of short repetitive sequences bearing foreign genes 
from invading pathogens have been identified and termed CRISPR (Makarova et al., 
2011). These repetitive CRIPSR genes can be transcribed into CRISPR RNAs 
(crRNAs) containing unique sequence homology to exogenous DNA (Brouns et al., 
2008). crRNAs then bind with a trans-activating crRNA (tracrRNA) which provides a 
scaffold to form a Cas9-crRNA-tracrRNA complex (Deltcheva et al., 2011). The crRNA 
directs the Cas9 nulcease to the target area and cleaves DNA in the presence of a 
short DNA sequence (NGG) immediately downstream from the target sequence (the 
protospacer adjacent motif (PAM)) (Deveau et al., 2008, Mojica et al., 2009).  This 
natural CRISPR/Cas9 system has now been engineered into a two-component system 
including a Cas9 nuclease and single guide RNAs (sgRNAs) that incorporates crRNA 
and tracrRNA together (Jinek et al., 2012, Cong et al., 2013, Mali et al., 2013b). The 
successful application of the CRISPR/Cas9 system to eukaryotic cells opens up a new 
era for the genome editing field. 
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Currently, the CRISPR/Cas9 system has revolutionized the genome editing field due 
to its easy construction, low cost and high efficiency. Numerous genetically modified 
cell lines and organisms have been established using CRISRP/Cas9 technology 
(Amitai and Sorek, 2016, Mohr et al., 2016, Lander, 2016, Waddington et al., 2016). 
The optimized methodology is not only developed for common research animal 
models or cell types, such as mice, flies,	Caenorhabditis elegans, stem cells, but has 
also been extended to other unconventional animal models, such as cattle, goats, pigs 
and monkeys (Ni et al., 2014, Hai et al., 2014, Niu et al., 2014, Wang, 2015). In addition, 
a large number of genetically modified plants have been generated using 
CRISPR/Cas9 technology (Liu et al., 2016). The application of CRISPR/Cas9 
technology to chicken biology and processes has attracted increasing interest from 
researchers.  
Chickens are not only an important livestock as a source of meat and eggs, but also 
a vital animal model for biological studies. From an evolutionary perspective, chicken 
fill the gap between mammals and other vertebrates and as such serve as a unique 
genome source for evolutionary studies. The diploid number of chromosomes in 
chickens is 78 (2n=78). The chromosomes include one pair of sex chromosomes and 
38 pairs of autosomes that can be further classified by size into 5 pairs of 
macrochromosomes, 5 pairs of intermediate chromosomes, and 28 pairs of 
microchromosomes (Hillier et al., 2004). In our studies, chicken interleukin-6 (ChIL-6) 
was chosen as a target gene due to its vital role in the pathogenicity of influenza virus 
infection (Burggraaf et al., 2014). The ChIL-6 gene is located on chromosome 2. The 
coding region of the ChIL-6 gene contains four exons and three introns, encoding a 
241-amino acid (aa) protein that shared 35% homology to human IL-6 (Schneider et 
al., 2001, Kaiser et al., 2004b). Preliminary gene editing work involved the use of two 
chicken cell lines; the fibroblast cell line, DF1, and the macrophage-like cell line, HD11.  
DF1 cells were established from chicken embryo fibroblasts and support the 
replication of various avian viruses, such as avian leucosis virus, infectious bursal 
disease virus and avian influenza virus (Himly et al., 1998). HD11 cells are a chicken 
macrophage-like cell line transformed with avian myelocytomatosis virus (MC29) 
(Beug et al., 1979). They are widely used to illustrate in vitro immune responses 
following infection or lipopolysaccharides (LPS) stimulation (Klasing and Peng, 1987, 
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Iqbal et al., 2005, Selvaraj and Klasing, 2006). In this chapter, CRISPR/Cas9 plasmids 
designed for human cells  were validated in both DF1 and HD11 cells. 
3.2 Results 
3.2.1 Construction of ChIL-6 gRNA plasmids and HDR template 
The ChIL-6 gene, consisting of four exons and three introns, encodes a 241-aa protein 
with a putative 47-residue N-terminal signal peptide. Ideally CRISPR gRNA design 
involves targeting regions closer to the N-terminus of a protein as the appearance of 
additional upstream frameshifts is more likely to create disrupted alleles. The ChIL-6 
gene has a high GC-content in exon 1 (up to 85%) making it difficult to amplify products 
using PCR for screening purposes. For practical reasons a target in exon 2 was 
chosen that lower GC-content (61%) (Figure 3.1A). The gRNA expression vector was 
generated successfully following the well-established Church lab protocol (Mali et al., 
2013b) and sequencing of results was shown in Figure 3.1B.  
Identification of genetically modified cells is a key consideration in the design of 
constructs. One of the important goals of this experiment was to conduct proof-of-
concept studies to demonstrate that CRISPR/Cas9 technology can be employed to 
modify genes in chicken cells. This would lay the foundation for the future 
generation/breeding of knockout/genetically modified chickens. As such, a strategy 
that allows high throughput screening of modified chicks was incorporated into the 
experimental design. To achieve this, a homology-directed repair (HDR) template was 
generated that allowed the insertion of a GFP expression cassette into the ChIL-6 
gene. Constitutive GFP expression is driven by a CMV promoter in the modified cells 
(or chicks in the future), that can be easily screened by visualization. The GFP 
expression cassette, contained a CMV promoter, an EGFP gene and a SV40 poly A 
tail that were amplified from the pEGFP-N1 plasmid (Figure 3.2A).  
The generation of a HDR template was completed using the strategy mentioned in 
methods chapter (See section 2.2.2). Two ChIL-6 gene homologous arms with a 
complementary sequence to GFP were amplified from chicken genomic DNA using 
two primer pairs (IL-6-UP-F& IL-6-UP-R, IL-6-DW-F& IL-6-DW-R) (Figure 3.2A). A 1.6 
kb GFP expressing cassette with an overhanging ChIL-6 gene was amplified from the 
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pEGFN-N1 vector using primers (GFP-F, &GFP-R), A 1.8kb HDR template was then 
generated using overlap PCR (Figure 3.2B), and contained a GFP expression 
cassette flanked by two ChIL-6 homologous arms (Figure 3.2D). The successful 
generation of a HDR template was confirmed by sequencing (Figure 3.2C).  
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Figure 3.1. Construction of a gRNA that targets ChIL-6 exon 2. (A) Schematic of the IL-6-gRNA-1 
targeting site in the ChIL-6 gene. Exons are shown as black boxes. The IL-6-gRNA-targeting sequence 
is shown in red and the PAM sequence is shown in green. (B) Sequencing analysis of the IL-6-gRNA-
1 construct. Positive clones were picked for sequencing and compared to the gRNA_Cloning Vector. 
The IL-6-gRNA-1 clone has a 60bp insertion that is highlighted in yellow and the ChIL-6 target sequence 
is boxed in red. 
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Figure 3.2. Generation of the HDR template. (A) PCR product showing the homologous arms and 
the GFP expression cassette. Lane 1: a 1.6kb PCR product amplified from the pEGFP-N1 plasmid 
using primers (GFP-F and GFP-R; Table 2.2). Lane 2: a 121bp PCR product amplified from chicken 
genomic DNA using primers (IL-6-UP-F and IL-6-UP-R; Table 2.2). Lane 3:  a 100bp PCR product 
amplified from chicken genomic DNA using primers (IL-6-DW-F and IL-6-DW-R; Table 2.2). (B) The 
PCR products from Figure 3.2A, lane 1-3, were purified and then mixed together at a ratio 1:1:1 to serve 
as a template for the overlapping PCR, followed by a second amplification using primers, IL-6-UP-F 
and IL-6-DW-R. A 1.8Kb product was generated as the HDR template. (C) The HDR template from (B) 
was ligated into pGEM-T vector and then sequenced. Sequencing analysis showed the HDR template 
was identical to the expected sequence. (D) Schematic of the HDR template. The HDR template 
incorporates the GFP expression cassette flanked by two ChIL-6 homologous arms. As such, the HDR 
template can independently express GFP in transfected cells. 
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3.2.2 Generation and purification of GFP-positive cells bearing a ChIL-6 
mutation 
GFP expression was visible in cells co-transfected with the IL-6-gRNA-1 vector, hCas9 
plasmid and the HDR template 24 hours after transfection in both DF1 and HD11 cells 
(Figure 3.3A). Cells that were transiently transfected with the HDR template usually 
became GFP-negative after 72 hours post-transfection. In order to isolate cells with 
permanent GFP integration into the genome, transfected cells were cultured 
continuously for 14 days. Clusters of GFP-positive DF1 and HD11 cells were observed 
14 days post-transfection, indicating genomic integration of GFP (Figure 3.3B). Single 
GFP-positive cells were then sorted into a well of a 96-well plate by FACS. GFP-
positive colonies expanded from a single cell were observed after two weeks (Figure 
3.3C), and were further expanded in a well of 24-well plate and culture flask (Figure 
3.3D). In total, two DF1-GFP (named DF1A and DF1B) clones and five HD11-GFP 
clones (named HD11A HD11B HD11C HD11D and HD11E) were obtained.  
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Figure 3.3. Generation and purification of GFP-positive cells bearing ChIL-6 mutations. (A) 
Monolayers of DF1 (upper panel) and HD11 cells (lower panel) were transfected with the IL-6-gRNA-1 
vector, hCas9 plasmid and the GFP HDR template. GFP fluorescence was observed in transfected cells 
24h post-transfection at 100x magnification. (B) A cluster of GFP-positive cells was observed in the cell 
culture 14 days post-transfection at 200x magnification. (C) The GFP-positive cells were sorted by flow 
cytometry and GFP-positive single-cell colonies were observed in a 96-well plate at 200x magnification. 
(D) single-cell colonies were observed under a fluorescent microscope at 100x magnification and then 
expanded in culture flasks for future study. These images are representative of other HD11 and DF1 
cell clones. 
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3.2.3 Characterization of the ChIL-6 gene in GFP-positive cells 
Continuous expression of GFP in sorted cells suggested integration of GFP into the 
host genome. To identify the insertion location of the GFP gene, a pair of primers were 
designed so that the forward primer (GFP-test-F) was located within the GFP gene 
and the reverse primer (GFP-test-R) was located within the ChIL-6 gene (Figure 3.4A). 
Gel electrophoresis showed a DNA band of 743bp for two DF1 GFP-positive cell 
clones, that confirm precise integration of GFP into the ChIL-6 gene in DF1-Clone A 
(DF1A) and DF1-Clone B (DF1B) (Figure 3.4B). A second pair of primers (IL-6-UP-F 
and IL-6-DW-R) were used to amplify the gRNA target area in the ChIL-6 gene (Figure 
3.4C). Gel electrophoresis showed a DNA band of ~350bp in DF1A in addition to the 
expected 2.1kb band that included GFP (Figure 3.4B). This result suggests that the 
GFP expression cassette was inserted into only one ChIL-6 gene allele. The ~350bp 
band was then purified for sequencing and the results indicated a deletion of 8 
nucleotides in the DF1A and a deletion of 2 nucleotides in DF1B clones (Figure 3.4E). 
As the size of the PCR product across the whole GFP insertion site from DF1B was 
~0.6 kb, i.e. smaller than the expected 2.1kb (Figure 3.4D), it may suggest that the 
HDR template was truncated during the integration process. Therefore, the DF1A 
clone (named as DF1-GFP hereafter) was chosen for further analysis.   
The same primers (GFP-test-F and GFP-test-R) were then used to screen HD11 GFP-
positive cells (Figure 3.5A). For HD11 GFP-positive clones A - E, no PCR product was 
amplified from extracted genomic DNA, (Figure 3.5B) suggesting that the GFP 
expression cassette was not integrated into the ChIL-6 gene as expected in HD11 
cells. When using the primer pair IL-6-UP-F and IL-6-DW-R to analyze mutations in 
the target area, two bands of ~350bp and ~200bp, were observed in all five HD11-
GFP clones A – E (Figure 3.5B) following gel electrophoresis. Both DNA bands were 
gel purified and sequenced and showed a deletion of 15 nucleotides in the ~350bp 
band (Figure 3.5E) and a 120 nucleotide deletion in the ~200bp band (Figure 3.5F). 
Interestingly, all five clones had the same deletion pattern suggesting they might have 
differentiated from the same original cell. Therefore, we randomly chose HD11-Clone 
E (named as HD11-GFP hereafter) for further analysis. 
From our sequencing results (Figure 3.4E, 3.5E and 3.5F), we observed that mutations 
occurred in ChIL-6 alleles. Only alleles bearing short deletions can be predicted 
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because mRNA splicing sites can be disrupted the boundary between exon2 and 3 by 
a large insertions or deletions. We showed that a WT ChIL-6 gene generates a 246 
amino acid (aa) protein (Figure 3.6A). In DF1-GFP cells, an 8-nuclotide-deletion in the 
ChIL-6 allele (Figure 3.4E) results in a frameshift after amino acid (aa) 125 and brings 
in a stop codon at aa153 (Figure 3.6B). In HD11-GFP cells, a 15-nucleotide-deletion 
in the ChIL-6 allele (Figure 3.5E) causes a 5aa deletion at aa121-125 (Figure 3.6C). 
We further tested the biological function of these mutated or truncated ChIL-6 proteins 
in the following sections.   
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Figure 3.4. Detection of changes in the ChIL-6 gene in GFP-positive DF1 cells. (A) Schematic of 
primers location GFP-test-F and GFP-test-R. (B) PCR products from wild type (WT) DF1 (Lane1), DF1A 
(Lane 2) and DF1B (Lane 3) genomic DNA. (C) Schematic of primers location; IL-6-UP-F and IL-6-DW-
R. (D) Primers, IL-6-UP-F and IL-6-DW-R, were used to amplify the whole target sequence from WT 
DF1 (Lane 1) DF1A (Lane 2) and DF1B (Land 3).  (E) The ~350bp PCR product (Lane 2 and Lane 3 in 
C) was gel purified for sequencing. Sequencing results indicate an 8-nuclotide deletion in clone DF1A 
and a 2-nuclotide deletion in clone DF1B. The target sequence of gRNA is labelled in a red box. 
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Figure 3.5. Detection of changes in the ChIL-6 gene in GFP-positive HD11. (A) Schematic of 
primers location; GFP-test-F and GFP-test-R. (B) PCR products amplified from genomic DNA extracted 
from WT HD11 cells (Lane 1), DF1A cells (Lane 2), HD11A cells (Lane 3), HD11B cells (Lane 4), HD11C 
cells (Lane 5), HD11D cells (Lane 6) and HD11E cells (Lane 7). (C) Schematic of primer location IL-6-
UP-F and IL-6-DW-R. (D) IL-6-UP-F and IL-6-DW-R primers were used to amplify the target sequence 
from WT HD11 cells (Lane 1), HD11A cells (Lane 2), HD11B cells (Lane 3), HD11C cells (Lane 4), 
HD11D cells (Lane 5) and HD11E cells (Lane 6). (E)  Sequencing results from the purified ~350bp band 
in (D). (F) Sequencing results from the purified ~200bp band in (D). The target sequence of gRNA is 
labelled in a red box. 
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Figure 3.6. Frameshift or deletion caused by mutations in the ChIL-6 gene. (A) Predicted protein 
sequence of the WT ChIL-6 gene. The CRISPR/Cas9 target site is highlighted in yellow. (B) Predicted 
protein sequence of the ChIL-6 gene bearing an 8-nucleotide deletion from DF1-GFP cells. The 
frameshift area is highlighted in red.  (C) Predicted protein sequence of the ChIL-6 gene carrying a 15-
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nucleotide deletion from HD11-GFP cells. Five amino acids are missing between two blue marked area. 
Methylation sites are highlighted in green. * indicates stop codon.  
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3.2.4 Analysis of ChIL-6 mRNA expression in GFP-positive cell lines  
The sequencing results from 3.2.3 confirmed mutations occurred in both ChIL-6 alleles.  
qRT-PCR was used to test if these mutations occurred in all sorted DF1-GFP and 
HD11-GFP cells. ChIL-6 mRNA expression was detected using a commercial Taqman 
primer/probe set and a custom primer/probe set as shown in Figure 3.7A. The 
commercial probe and primers spanned the boundary of exon 3 and exon 4, a position 
that is distant from the IL-6-gRNA target site in exon 2 (Figure 3.7A). The custom-
made primers/probe set (Forward primer: 5’-GAACAACCTCAACCTGCCC-3’, 
Reverse primer: 5’-CAGGCATTTCTCCTCGTCG-3’, Probe:5’-ACGGCTGCCTGCT 
CGGCCGG-3’) targeted exon2 and the probe sequence overlapped with the gRNA-
targeted site (Figure 3.7A). HP H5N1 (A/chicken/Vietnam/0008/2004) infection 
induces high levels of ChIL-6 in both DF1 and HD11 cells (Ye et al., 2015). HP H5N1 
virus was used to infect DF1-GFP and HD11-GFP cells and WT DF1 and HD11 cells 
(controls). Actin gene expression was used as a positive control. ChIL-6 mRNA 
expression was detected by both primers/probe sets in WT DF1 and WT HD11 cells 
post H5N1 virus infection (Figure 3.7B and Figure 3.7D). In contrast, the ChIL-6 mRNA 
expression was only detected by the commercial primers/probe set and not by the 
custom-made primers/probe set in DF1-GFP and HD11-GFP cells post H5N1 infection 
(Figure 3.7C and Figure 3.7E). Undetectable ChIL-6 mRNA using the custom-made 
primers/probe set confirms the presence of mutations in the target area, as shown by 
sequencing (Figure 3.4E, 3.5E and 3.5F). Having established this our next step was 
to check if the mutations in the ChIL-6 alleles caused a loss of function.  
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Figure 3.7. Detection of ChIL-6 mRNA expression with a custom-designed ChIL-6 qRT-PCR 
primer/probe set. (A) Schematic of the custom-made ChIL-6 probe (black line) and commercial ChIL-
6 probe (blue line). ChIL-6 mRNA consists of four exons (Exon1: Orange line, Exon2: Purple line, Exon3: 
Yellow line, Exon4: Green line). The ChIL-6 commercial probe used in this study spans the boundary 
of exon 3 and exon 4. The custom-designed probe is located in exon 2, which overlaps with the IL-6-
gRNA-1 target sequence (Red block). WT DF1 cells (B), DF1-GFP cells (C), WT HD11 cells (D) and 
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HD11-GFP (E) were infected with HP H5N1 virus at a MOI of 0.01. Total cellular RNA was extracted for 
qRT-PCR. Actin mRNA expression is shown as a blue line. ChIL-6 mRNA amplified using a commercial 
probe is shown as a green line. ChIL-6 mRNA amplified using the custom-made probe is shown as a 
yellow line. This experiment was repeated in triplicate and one representative curve is shown. 
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3.2.5 ChIL-6 protein function in GFP-positive cell lines. 
We started by assessing ChIL-6 protein expression in DF1-GFP and HD11-GFP cells 
using Western blot analysis in combination with a commercial anti-chicken IL-6 
antibody (AbD Serotec, USA). Multiple protein bands were detected suggesting poor 
specificity of this antibody (data not shown). Given the lack of appropriate chicken 
antibodies we used the 7TD1 cell proliferation bioassay to assess ChIL-6 function in 
these GFP-positive cell lines. 7TD1 cells are dependent on IL-6 protein for proliferation. 
Recombinant ChIL-6 protein was initially used to generate a standard curve with a 
linear range between 10ng/ml and 10-5ng/ml (Figure 3.8A). For DF1-GFP and HD11-
GFP cell lines, 20ml supernatant post 24h LPS stimulation was collected and 
concentrated into 20ul. Concentrated supernatant was then added to the 7TD1 cells 
for 72h and cell numbers were measured by luminescence signal following the addition 
of CellTiter-GloR 2.0 Reagent. ChIL-6 concentration was calculated using a standard 
curve. ChIL-6 protein expression (by proliferation) was detected in WT cells (an 
average of 4pg/ml in WT DF1 cells and an average of 2pg/ml in WT HD11 cells), and 
not in DF1-GFP (Figure 3.8B) or HD11-GFP cells (Figure 3.8C). These results confirm 
the deletion of ChIL-6 gene and disruption of ChIL-6 protein expression in both DF1-
GFP and HD11-GFP cells. From this point on, these two IL-6 knockout cell lines are 
named as ChIL-6-/-  DF1 and ChIL-6-/- HD11.  
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Figure 3.8. ChIL-6 expression and function in GFP-positive cells measured using the 7TD1 
bioassay. (A) Standard curved established using recombinant ChIL-6 protein with a liner range 
between 10ng/ml and 10-5ng/ml. 7TD1 cells were cultured with ChIL-6 for 72h and cell number 
(proliferation) was measured according to luminescence signal following the addition of CellTiter-GloR 
2.0 Reagent. WT DF1 and DF1-GFP (B) and WT HD11 and HD11-GFP cells (C) were stimulated with 
LPS (1ng/ml) for 24h and supernatants were harvested and concentrated using an Amicon Ultra-15 
Centrifugal Filter Units. 7TD1 cells were cultured in the presence of supernatant. Cell proliferation was 
measured after 4 days using CellTiter-Glo® 2.0 (Promega). ChIL-6 concentrations were calculated 
using a standard curve. Data represents the mean ± SD using a student's t-test from three replicates. 
*p<0.05.  
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3.3 Discussion 
With the advent of CRISPR/Cas9 technology, the technology has expanded rapidly  to 
include  a large range of the plants and animals (Reardon, 2016). It also includes, the 
first commercially available mushroom engineered to resist browning (Waltz, 2016). 
However, genome editing in chickens lags far behind other species. The 
CRISPR/Cas9 plasmids used in this chapter was released in 2013 and were optimized 
for human cell lines (Mali et al., 2013b). In this chapter, the CRISPR/Cas9 plasmids 
were used in chicken cell lines for proof-of-concept experiments to demonstrate that it 
is feasible to precisely modify the chicken genome using CRISPR/Cas9 technology. 
Two chicken cell lines (DF1 and HD11) were used to validate the acquired plasmids.  
CRISPR/Cas9 technology has been engineered and optimized to produce double-
strand breaks (DSBs) precisely and efficiently in genomic DNA of eukaryotic cells 
(Jinek et al., 2013). The occurrence of DSBs subsequently triggers the DNA repair 
process. Two main pathways are involved in DNA repair: homologous recombination 
(HR) and non-homologous recombination ending jointing (NHEJ) (Sonoda et al., 2006). 
Whether HR or NHEJ is dominant in the repair process is regulated by a range of 
factors such as cell type, chromosomal location and cell cycle phases (Sonoda et al., 
2006, Shrivastav et al., 2008). In our construct design, HR was expected to incorporate 
the GFP expression cassette gene into the ChIL-6 gene, to disrupt gene expression 
and establish a selective marker at the same time. The results showed that in DF-1 
cells, the GFP gene was precisely inserted into one ChIL-6 allele and the second ChIL-
6 allele contained mutations as a result of the error-prone NHEJ repair. In HD11 cells, 
both ChIL-6 alleles were modified through the NHEJ repair process. NHEJ is normally 
the dominant DNA repair process (Deriano and Roth, 2013). However, HR is a vital 
pathway that introduces precise modifications including single nucleotide mutations 
and insertion of screening markers. Increasing the frequency of HR in modified cells 
is challenging in genome editing and a lot of effort has been made to optimize this 
repair system. Recent studies showed that the NHEJ process can be inhibited by con-
transfection of Scr7 (a DNA ligase inhibitor) into cells (Chu et al., 2015, Maruyama et 
al., 2015, Ma et al., 2016). These strategies should be considered in future studies to 
steer the DNA repair process towards HR to achieve the precise modifications. 
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Random integration of a foreign gene into the host genome is one of the major issues 
in gene editing. Therefore, recent studies, involving the generation of animal models, 
often inject foreign mRNA or protein into mammalian embryos instead of DNA 
plasmids to avoid random integration (Sato et al., 2015, Hashimoto and Takemoto, 
2015). In our study, random insertion was observed in HD11 cells. The HD11 cell line 
used in our work has been transformed by avian leukemia virus which is capable of 
integrating foreign genes into the host genome (Beug et al., 1979). It is possible that 
this is the reason for random insertion of the GFP gene in our study. In contrast DF1 
cells are free of avian leukemia virus and random gene insertion was not observed 
throughout our study. To our knowledge, our study is the first to modify gene 
expression in HD11 cells and the results suggest that this cell line is not a good 
candidate for genome editing. 
Off-target effects are a concern for the future application of CRISPR/Cas9 technology. 
A numbers of strategies have been established to avoid this including the use of a 
novel Cas9 variant with high-fidelity (Carroll and Beumer, 2014), use of double nickase 
Cas9 (Ran et al., 2013a) and optimization of gRNA/Cas9 ratios (Hsu et al., 2013). 
Another challenge is to develop a sensitive and cost-effective method to detect off-
target effects on a genome-wide scale. Website-based prediction and T7 
endonuclease assays have been widely used in previous studies. This strategy was 
recently used to detect mutations involving CRISPR/Cas9 modifications in chicken 
DF1 cells (Bai et al., 2016, Zuo et al., 2016) and undetectable off-target was observed . 
However, this strategy does have obvious limitations. Firstly, its predictions are based 
on the assumption that the off-target sequence is similar to the target gene. This 
ignores off-targets with low sequence homology (Zhang et al., 2015). Secondly, the 
sensitivity of T7 endonuclease is poor and can only measure off-target mutations at 
frequencies >1% (Cho et al., 2013). It is therefore preferable to establish whole-
genome based methods to test the genome modifications. Very recently, a study using 
whole-genome sequencing to identify off-target mutations in CRISPR/Cas9-generated 
mice showed a very high frequency of unexpected mutations (117 small deletions or 
insertions, 1397 single-nucleotide variants). These sites shared a low sequence 
homology to the target site (KA et al., 2017). This result indicates the importance of 
choosing a sensitive method to detect off-target mutations. Currently, whole genome 
sequencing is expensive. With the development of improved detection technologies, 
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it will be interesting to check off-target mutations in chicken following use of 
CRISPR/Cas9 protocols. 
The validation of CRISPR technology in chicken cell lines is required prior to extending 
its application in chickens. Our study shows that humanized plasmid constructs can 
be used to modify the chicken genome. The modified DF-1 and HD-11 cells can now 
be used for future studies to investigate the role of ChIL-6 in influenza virus infection. 
These proof-of-concept experiments also suggest that it may be possible to generate 
a genetically modified chicken using CRISPR-Cas9 system in the future. 
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Chapter 4   The role of ChIL-6 in influenza virus 
pathogenicity 
 
4.1 Introduction 
Highly pathogenic avian influenza (HPAI) H5N1 infection can result in overproduction 
of cytokines, in a process known as  “Cytokine Storm” or “hypercytokinemia”, that is 
thought to contribute to high levels of mortality (Yuen and Wong, 2005, de Jong et al., 
2006). A large variety of molecules take part in cytokine storm including; interferons, 
interleukins, chemokines, TNFs and colony-stimulating factors (CSFs) (Tisoncik et al., 
2012). The exact reason and mechanism of why cytokine storm occurs is still not 
known, however the overproduction of some key cytokines such as IL-6, TNF-a, and 
interferons are thought to trigger this phenotype (Tisoncik et al., 2012). Data from the 
clinic shows that IL-6 expression is much higher in severe and fatal cases of H5N1, 
H7N9 and pandemic H1N1 infection when compared to the non-severe cases (Alam 
et al., 2012, To et al., 2010, Chi et al., 2013). These studies suggest that over-
production of IL-6 following influenza virus infection may contribute to viral 
pathogenicity of human infection. 
IL-6 is a cytokine that was characterized by functional pleiotropy and redundancy. IL-
6 is secreted by various cell types and is involved in a range of cellular activities 
including proliferation, differentiation and apoptosis (Hunter and Jones, 2015). IL-6 
also plays a key role in innate and adaptive immunity as IL-6 knockout (IL-6-/-) mice 
are susceptible to bacterial and viral infections (Kopf et al., 1994, Poll et al., 1997, 
Hoge et al., 2013). In innate immunity, IL-6 is thought to mediate neutrophil recruitment 
to sites of infection through activation of signal transducer and activator of transcription 
3(STAT3) (Jones et al., 2006).  Moreover, IL-6 is thought to link innate and adaptive 
immune responses through regulation of CD4+ T cell differentiation (Dienz and Rincon, 
2009). IL-6 has been shown to promote CD4+Th2 differentiation by increasing IL-4 
expression through activation of the nuclear factor of activated T cells (NFAT) (Diehl 
and Rincón, 2002). During the adaptive immune response, IL-6 has been shown to 
promote maturation of plasma B cells and secretion of immunoglobulin G (IgG) 
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(Yoshizaki et al., 1984). This is evidenced through the observation of lower IgG 
production in the IL-6-/- mice post vesicular stomatitis virus infection when compared 
to wild type control mice (Kopf et al., 1994). 
IL-6 knockout (IL-6-/-) mice have been used extensively to understand the role of IL-6 
in influenza virus pathogenicity. As in humans, high IL-6 expression is observed in HP 
H5N1-infected mice (Szretter et al., 2007, Salomon et al., 2007). IL-6-/- mouse were 
therefore used to assess pathogenicity following HP H5N1 infection and showed 
comparable survival when compared to WT controls. (Szretter et al., 2007, Salomon 
et al., 2007). Furthermore, IL-6-/- mice infected with mouse-adapted H1N1 virus 
showed that IL-6 was protective against influenza virus infection. However, the 
protective role of IL-6 is controversial. Dienz et al., suggested that IL-6 can facilitate 
viral clearance by supporting neutrophil development in the lung (Dienz et al., 2012). 
In contrast, Lauder et. al, thought the dysregulated immune responses and 
compromised anti-viral T cell responses caused by a lack of IL-6 was responsible for 
severe lung damage in PR8 infected IL-6-/- mice (Lauder et al., 2013). Additional 
studies showed that depletion of IL-6 can increase pathogenicity by enhancing 
fibroblast accumulation and inhibiting extracellular matrix turnover (Yang et al., 2017). 
Unlike the mouse, chickens are more susceptible to HP H5N1 infection. Chickens 
infected with HP H5N1 chicken die between 24 to 48 hours after infection (Schat et 
al., 2012) and show evidence of a cytokine storm (Suzuki et al., 2009, Burggraaf et al., 
2014). Among the cytokines produced, IL-6 expression is increased in multiple organs 
(70 fold higher in lung, 100 fold higher in liver, 80 fold higher in spleen) (Burggraaf et 
al., 2014). The chicken immune system is different from that seen in mammals and 
ChIL-6 shows only 35% homology when compared to mammalian IL-6 (Kaiser et al., 
2004b). In this chapter we ask whether ChIL-6 functions in a manner similar to 
mammalian IL-6 following influenza virus infection. To determine this, ChIL-6-/- cell 
lines, DF1 and HD11 generated in chapter 3, were infected with two influenza virus 
strains, mammalian PR8 H1N1 virus and HP A/chicken/Vietnam/0008/2004 H5N1 
(H5N1) virus and functional assays performed. Our results showed that cell lines 
lacking ChIL-6 showed increased levels of influenza viral replication.  
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4.2 Results 
4.2.1 Increased influenza virus replication in ChIL-6-/- cell lines 
PR8 H1N1 viruses have been widely used to study the role of IL-6 in the pathogenicity 
following infection (Kozak et al., 1997, Dienz et al., 2012, Lauder et al., 2013). PR8 
viruses have also been used to infect chicken cell lines in our laboratory (Ye et al., 
2015). We used PR8 virus (MOI 1) to infect WT and ChIL-6-/- -DF1 and -HD11 cell 
lines in the absence of trypsin (DF-1 and HD11 cell are highly sensitive to trypsin) and 
one round of replication was analyzed at 24h post-infection. This analysis is possible 
given that viruses amplified in eggs, such as PR8, have a pre-cleaved HA and can 
undergo one round of replication (Hamilton et al., 2014, Kandeil et al., 2014). Loss of 
ChIL-6 expression in DF1 and HD11 cells resulted in higher virus titers by 2 fold and 
3 fold respectively compared to the WT counterparts. (Figure 4.1). WT and ChIL-6-/- -
DF1 and -HD11 cells were also infected with HPAI H5N1 (MOI of 0.01), and influenza 
virus Matrix (M) gene expression analyzed using qRT-PCR as an indicator of viral 
replication (Ye et al., 2015). Similar to the PR8 virus infection, influenza virus 
replication was higher in ChIL-6-/- -DF1 (2-fold higher) and -HD11 cells (1.5-fold higher) 
when compared to WT -DF1 and -HD11 cells controls (Figure 4.2).   
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Figure 4.1. Influenza PR8 H1N1 virus replication in ChIL-6-/- -DF1 and -HD11 cells. WT and ChIL-
6-/- -DF1 (A) and -HD11 (B) cells were infected with PR8 virus at an MOI of 1. After 24 hours, 
supernatants from infected cells were collected and virus titers were determined using a plaque assay. 
Data shown are the means ± SD from three individual experiments ** p < 0.01 using a student’s t-test. 
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Figure 4.2. Matrix gene expression in H5N1-infected ChIL-6-/- -DF1 and -HD11 cells. WT and ChIL-
6-/- -DF1 (A) and -HD11 (B) cells were infected with HPAI H5N1 virus at an MOI of 0.01. After 24 hours, 
supernatants from infected cells and M gene expression analyzed using qRT-PCR. M gene expression 
was normalized to β-actin mRNA using the 2–DDCT method where expression levels were determined 
relative to H5N1-infected WT cell controls. Data are expressed as fold-changes and show the means ± 
SD from three individual experiment. **p < 0.01; ***p < 0.001 using a student’s t-test. 
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4.2.2 Expression of immune-related genes in uninfected and infected ChIL-6-/- -
DF1 and -HD11 cells  
To investigate the impact of ChIL-6 deficiency on the expression of other immune-
related genes following influenza virus infection, LPS induced necrosis factor-alpha 
(LITAF), Interleukin-10 (IL-10), Interferon-beta (IFN-𝛽) and Myxovirus resistance (Mx) 
gene were analyzed in infected ChIL-6-/- -DF1 and -HD11 cells. To date,  TNF-a, a 
vital pro-inflammatory cytokine involved in the acute phase of influenza virus infection 
(Clark, 2007), has not as yet been characterized in chickens. Chicken LITAF is a well 
characterized transcription factor that is thought to regulate the expression of  TNF-a 
in chickens by binding the TNF-a promoter (Hong et al., 2006). We therefore analyzed 
LITAF expression in uninfected and infected ChIL-6-/- cell lines. As shown in Figure 
4.3, the LITAF gene expression was similar between uninfected WT and ChIL-6-/- DF1 
cells (Figure 4.3A) and between uninfected WT and ChIL-6-/- HD11 cells (Figure 4.3B). 
Moreover, PR8 infection had no impact on the expression of LITAF in both DF1 (Figure 
4.3A) and HD11 cells (Figure 4.3B). In contrast, H5N1 infection significantly increased 
expression of LITAF in both WT DF1 (15-fold) (Figure 4.3C) and HD11 cells (4-fold) 
(Figure 4.3D). Notably, H5N1-infected ChIL-6-/- -DF1 and -HD11cells had 2 fold and 
1.5 fold respectively higher LITAF gene expression when compared to H5N1-infected 
WT counterparts (Figure 4.3C, 4.3D). 
IL-10 is a cytokine with anti-inflammatory properties that plays a vital role in regulating 
inflammatory responses following influenza virus infection (Saraiva and O'garra, 2010, 
Sun et al., 2009). Basal IL-10 gene expression in uninfected ChIL-6-/- -DF1 (Figure 
4.4A) and -HD11(Figure 4.4B) cells was 0.5-fold and 2-fold respectively higher when 
compared to uninfected WT counterparts. PR8 infection increased expression of IL-
10 by 2-fold in ChIL-6-/- HD11 cells when compared to WT HD11 cells (Figure 4.4B), 
but had no impact on the expression of IL-10 when comparing ChIL-6-/- DF1 and WT 
DF1 cells (Figure 4.4A). Similarly, H5N1-infected ChIL-6-/- HD11 cells showed 2-fold 
higher IL-10 gene expression when compared to H5N1-infected WT HD11 cells 
(Figure 4.4D). No changes in IL-10 gene expression were observed between H5N1-
infected ChIL-6-/- DF1 and WT DF1 cells (Figure 4.4C). 
IFN-𝛽 is a type I interferon that can trigger innate immune responses against influenza 
A viruses (Koerner et al., 2007). IFN-𝛽 gene expression in uninfected ChIL-6-/-  DF1 
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cells is 2.5-fold higher than that observed in uninfected DF1 cells (Figure 4.5A), whilst 
no differences were observed between uninfected WT and ChIL-6-/-  HD11 cells 
(Figure 4.5B). In WT DF1 cells, PR8 and H5N1 infection increased IFN-𝛽  gene 
expression by 5 and 50 fold respectively (Figure 4.5A, 4.5C). In contrast, only H5N1 
infection increased IFN-𝛽 gene expression (50 fold) in WT HD11 cells (Figure 4.5D).  
The Mx protein is an interferon-induced GTPase, that has anti-influenza properties in 
humans and mice (Iwasaki and Pillai, 2014). Basal Mx gene expression in uninfected 
ChIL-6-/- -DF1 (Figure 4.6A) and -HD11 cells (Figure 4.6B) was significantly lower (0.1-
fold and 0.01-fold respectively) than the uninfected WT counterparts. PR8 and H5N1 
infection increased Mx gene expression in WT and ChIL-6-/- DF1 cells compared to 
uninfected WT or ChIL-6-/- DF1 control cells (Figure 4.6A, 4.6C). PR8-infected WT 
HD11 cells showed increased Mx gene expression (Figure 4.6B) while H5N1-infected 
WT HD11 showed decreased Mx gene expression (Figure 4.6D).  
The impact of ChIL-6 absence in DF1 and HD11 cells is both cell-dependent and virus 
strain-dependent. Considering the pleiotropic role of IL-6 in inflammatory responses, 
it is not surprising we observed differences in immune gene expression in ChIL-6-/- 
cells. In the present study, aberrant expression of immune genes (Figure 4.3, 4.4, 4.5, 
4.6) is thought to have contributed to higher virus replication and may have other 
downstream effects. As such we analyzed the cell proliferation and apoptosis in 
experiments described below. 
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Figure 4.3. LITAF gene expression in ChIL-6-/- -DF1 and -HD11 cells infected with H5N1. WT and 
ChIL-6-/- -DF1 (A and C) and -HD11 cells (B and D) were infected with PR8 virus at an MOI of 1 (A and 
B) or H5N1 virus at an MOI of 0.1 (C and D). After 24 hours, the total cellar RNA was extracted for qRT-
PCR analysis. LITAF gene expression was normalized to β-actin mRNA using the 2–DDCT method 
where expression levels were determined relative to uninfected WT cell controls. Data are expressed 
as fold-changes and are the means ± SD from three individual experiments. *p < 0.05; ** p < 0.01; *** 
p < 0.001; NS, not significant using a student’s t-test. 
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Figure 4.4. IL-10 gene expression in ChIL-6-/- HD11 cells infected with PR8 or H5N1 viruses. WT 
and ChIL-6-/- -DF1 (A and C) and -HD11 cells (B and D) were infected with PR8 virus at an MOI of 1 (A 
and B) or H5N1 virus at an MOI of 0.1 (C and D). After 24 hours, the total cellar RNA was extracted for 
qRT-PCR analysis. IL-10 gene expression was normalized to β-actin mRNA using the 2–DDCT method 
where expression levels were determined relative to uninfected WT cell controls. Data are expressed 
as fold-changes and are the means ± SD from three individual experiment. *p < 0.05; **p < 0.01; ***p < 
0.001; NS, not significant using a student’s t-test. 
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Figure 4.5. IFN-β gene expression in ChIL-6-/- -DF1 and -HD11 cells infected with H5N1 or PR8. 
WT and ChIL-6-/- -DF1 (A and C) and -HD11 cells (B and D) were infected with PR8 virus at an MOI of 
1 (A and B) or H5N1 virus at an MOI of 0.1 (C and D). After 24 hours, the total cellar RNA was extracted 
for qRT-PCR analysis. IFN-𝜷 gene expression was normalized to β-actin mRNA using the 2–DDCT method 
where expression levels were determined relative to uninfected WT cell controls. Data are expressed 
as fold-changes and are the means ± SD from three individual experiment. * p < 0.05; ** p < 0.01; *** p 
< 0.001; NS, not significant using a student’s t-test. 
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Figure 4.6.Myxovirus resistance (Mx) gene expression in ChIL-6-/- -DF1 and -HD11 cells. WT and 
ChIL-6-/- -DF1 (A and C) and -HD11 cells (B and D) were infected with PR8 virus at an MOI of 1 (A and 
B) or H5N1 virus at an MOI of 0.1 (C and D). After 24 hours, the total cellar RNA was extracted for qRT-
PCR analysis. Mx gene expression was normalized to β-actin mRNA using the 2–DDCT method where 
expression levels were determined relative to uninfected WT cell controls. Data are expressed as fold-
changes and are the means ± SD from three individual experiment. * p < 0.05; ** p < 0.01; *** p < 0.001; 
NS, not significant using a student’s t-test. 
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4.2.3 Reduced cell proliferation in ChIL-6-/- DF1 cells 
IL-6 has been found to be involved in the proliferation of different cell types. IL-6 can 
promote B cell and T cell proliferation through activation of the JAK/STAT pathway 
(Hirano et al., 2000). We tested proliferation of uninfected ChIL-6-/- -DF1 and -HD11 
cells and compared this to WT controls. WT -DF1 and -HD11 cells are normally 
subcultured every 3-4 days. Therefore, we focused on cell proliferation from day 1 to 
day 4. As shown in Figure 4.7A, uninfected ChIL-6-/- DF1 cells proliferated less 
between days 2 to 4 when compared to WT controls.  In contrast, a lack of ChIL-6 has 
no impact on cell proliferation between days 1 to 4 in HD11 cells (Figure 4.7B).  
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Figure 4.7. Cell proliferation of ChIL-6-/- DF1 and HD11 cells. WT and ChIL-6-/- -DF1 (A) and -HD11 
(B) cells were cultured in 96-well plates starting at 10 000 cells per well. Luminescence corresponding 
to cell numbers was recorded every 24h using the CellTiter-Glo Luminescent Cell Viability Assay Kit 
(seen in 2.3.5) and the Synergy HT plate reader. The results shown are the means ± SD from three 
individual experiment. * p < 0.05; ** p < 0.01 using a student’s t-test. 
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4.2.4. Irregular caspase3/7 activity in ChIL-6-/- DF1 and HD11 cells following PR8 
virus infection 
Apoptosis of infected cells can limit pathogen replication and is a vital factor 
determining the outcome of infection (Barber, 2001). Previous data has showed that 
IL-6 can protect the neutrophils from influenza virus-induced apoptosis by increasing 
the expression of the anti-apoptosis gene, Mcl-1 (Dienz et al., 2012). Here, we 
investigated apoptosis in infected ChIL-6-/- -DF1 and -HD11 cells. Apoptosis is 
regulated by a family of protein-cleaving enzymes, termed caspases (Thornberry and 
Lazebnik, 1998). These caspases are divided into two groups based on the function; 
initiator caspases (such as caspase 8,9) and executioner caspases (such as caspase 
3,7) (Salvesen and Ashkenazi, 2011). A luminescent assay is widely used to test 
caspase3/7 activity (Bayascas et al., 2002). In this study, we used a Caspase-Glo 3/7 
Assay Kit to test caspase3/7 activity as shown in 2.3.7. The results show that basal 
levels of caspase3/7 activity are lower in ChIL-6-/- DF1 cells when compared to WT 
controls (Figure 4.8A), but higher in ChIL-6-/- HD11 cells when compared to WT 
counterparts (Figure 4.8B). This was also true following PR8 infection (DF1 PR8 vs 
ChIL-6-/- DF1 PR8; HD11 PR8 vs ChIL-6-/- HD11 PR8) (Figure 4.8). These results 
suggest that the role of ChIL-6 in apoptosis maybe be cell dependent.  
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Figure 4.8. Caspase 3/7 activity in ChIL-6-/- -DF1 and -HD11 cells. WT and ChIL6-/- -DF1 (A) and -
HD11 cells (B) were infected with PR8 virus at a MOI of 1. Uninfected WT cells were used as negative 
controls. Caspase 3/7 activity was measured by using a Promega caspase-Glo 3/7 assay system. The 
results are shown as the means ± SD from three individual experiment. * p < 0.05; ** p < 0.01; *** p < 
0.001 using a student’s t-test. 
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4.2.5 ROS production in ChIL-6-/- DF1 and HD11 cells 
ROS is a natural product of cell metabolism that is involved in a range of cell signaling 
events (Thannickal and Fanburg, 2000). Work in the Stambas laboratory has found a 
correlation between ROS production and cytokine expression following influenza virus 
infection of chicken DF1 and HD11 cells (Ye et al., 2015). In addition, the generation 
of ROS in nasal epithelium following influenza virus infection has been found to limit 
viral replication (Kim et al., 2015). The relationship between IL-6 production and ROS 
expression is ambiguous. IL-6 has been found to stimulate ROS production in human 
myeloma cells (Brown et al., 2012), however, porphyromonas gingivalis-induced ROS 
is thought to enhance expression of IL-6 in human epithelial cells (Wang et al., 2014a).  
Here, we analyzed ROS production in PR8-infected ChIL-6-/- -DF1 and -HD11 cells. 
Uninfected ChIL-6-/- -DF1 and -HD11 cells produce low basal levels of ROS when 
compared to WT -DF1 (Figure 4.9A) and -HD11 cells (Figure 4.9B), respectively. 
Interestingly, PR8 virus infection only enhanced ROS production in WT cells but not 
in the ChIL-6-/- cells (Figure 4.9).  
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Figure 4.9. ROS production in ChIL-6-/- -DF1 and -HD11 cells. WT and ChIL6-/- -DF1 (A) and -HD11 
cells (B) were infected with PR8 virus at a MOI of 1. Uninfected WT cells were used as a negative 
control. The production of ROS was measured using the CellROX Deep Red reagent. Cell nuclei was 
stained by DAPI. ROS fluorescence was then quantified and normalized by cell number using a 
CellInsight system. The result showed the mean ROS fluorescence ± SD from three individual 
experiments. *** p < 0.001 using a student’s t-test.  
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4.2.6 Restoration of IL-6 antiviral activity 
IL-6 rescue experiments were performed to validate virus titer results obtained in ChIL-
6-/- cells (Figure 4.1, 4.2). Preliminary experiments showed altered cytokine expression 
in HD11 cells only when commercial recombinant chicken IL-6 protein was added to 
culture (data not shown). As such an IL-6 rescue experiment was only performed in 
ChIL-6-/--HD11 cells. The results showed that addition of recombinant chicken IL-6 
partially lowers virus titer in the PR8-infected IL-6-/- HD11 cells (Figure 4.10). This 
result confirms an antiviral role for ChIL-6 in HD11 cells. 
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Figure 4.10. Exogenous chicken IL-6 recombinant protein demonstrates anti-viral activity in 
PR8-infected IL-6-/--HD11 cells. WT and ChIL-6-/- -HD11 cells were infected with PR8 virus at MOI of 
1. Recombinant ChIL-6 (10ng/ml) was added to culture media of infected HD11 ChIL-6-/- cells and after 
24h supernatant was collected and plaque assays performed. The result shown is the mean ± SD from 
three individual experiments. * p < 0.05; *** p < 0.001 using a student’s t-test. 
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4.3 Discussion 
IL-6 is a pleiotropic cytokine that is involved in inflammation, infection and cancer. The 
role of IL-6 in the pathogenicity of influenza virus infection has been extensively 
studied in murine models. Lack of IL-6 has been shown to compromise antiviral 
responses in influenza virus-infected mice (Dienz et al., 2012, Lauder et al., 2013). 
Results from our current in-vitro work suggests that ChIL-6 also functions as a 
protective, antiviral cytokine in chicken cell lines. 
In mammalian species, the function of IL-6 is highly dependent on cell type. IL-6 will 
promote B cell proliferation (Friederichs et al., 2001) but can also inhibit dermal 
fibroblast proliferation (Mihara et al., 1996). IL-6 can act as both a pro-inflammatory or 
anti-inflammatory cytokine in the same cell type depending on its concentration or the 
presence of other modulators (Scheller et al., 2011). In this study, two chicken cell 
lines (DF1 and HD11) have been used. DF1 and HD11 cell lines are the most 
commonly used chicken cell lines for in vitro studies (Himly et al., 1998, Lee et al., 
2008, Moresco et al., 2010, Bortz et al., 2011, Liniger et al., 2012). DF1 cells originated 
from a fibroblast progenitor and HD11 cells a macrophage progenitor, with both used 
in influenza studies (Ye et al., 2015).  Previous studies have shown that  polyIC 
stimulus can increase the expression of ChIL-6 in HD11, but not DF1 cells, indicating 
the potential for differential immune responses between these cell lines (Karpala et al., 
2008). In the present study, expression of various cytokines in ChIL-6-/- cells (DF1 or 
HD11) following infection varies in a cell-dependent fashion as seen in Figure 4.3-4.6.  
In mammalian species, IL-6 functions as a key mediator of immune homeostasis. Lack 
of IL-6 in mice has been found to result in higher expression of pro-inflammatory 
cytokines, such as TNF-a and IFN-a, post influenza virus infection (Lauder et al., 
2013). Similarly, our study found that a lack of ChIL-6 results in higher expression of 
LITAF (a TNF-like molecule) in DF1 and HD11 cells post H5N1 infection (Figure 4.3C, 
4.3D). As well as a pro-inflammatory molecule, IL-6 also functions as an anti-
inflammatory cytokine (Lauder et al., 2013). In our present study, anti-inflammatory IL-
10 expression was increased in ChIL-6-/- HD11 cells post PR8 or H5N1 infection 
(Figure 4.4B, 4.4D). This upregulation may be an attempt to compensate for the loss 
of ChIL-6 in ChIL-6-/- HD11 cells.  
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The host-pathogen interaction between infected-cells and viruses involves a series of 
cellular functions such as cell proliferation and apoptosis. As influenza-viruses have 
evolved they have developed strategies to manipulate these activities to facilitate 
replication (Alcami and Koszinowski, 2000). In contrast, infected-cells have subverted 
these activities to fight viral infection (Kreijtz et al., 2011). In mice, IL-6 was reported 
to protect lung epithelial cells and neutrophils from influenza virus-induced apoptosis 
(Dienz et al., 2012, Yang et al., 2017). Moreover, IL-6 can also inhibit the growth of 
lung fibroblasts to lessen the lung damage caused by influenza infection (Yang et al., 
2017). In the present study, ChIL-6 was found to play a key role in regulating cell 
apoptosis and proliferation. ChIL-6 deficiency led to increased apoptosis in HD11 cells 
and resulted in a decreased cell proliferation and apoptosis in DF1 cells.   
The mechanism by which ChIL-6 regulates the immune response or cellular activity in 
this study is not clear. The Chicken IL-6R (ChIL-6R) has been previously characterized  
(Jones and Rose-John, 2002).  We have been unable to amplify the ChIL-6R gene 
using the published sequence due perhaps to differences in the breed of chicken. We 
did not investigate ChIL-6 signaling further in this study. In mammalian species, IL-6 
signaling occurs through the JAK-Start3 pathway once it has bound IL-6 receptor (IL-
6R) and glycoprotein 130 (GP130). Activated STAT3 can regulate the expression of 
more than 1000 genes, including cyclin D and c-Myc genes that control cell 
proliferation; orcBcl-xL a gene that regulates cell apoptosis (Cressman et al., 1996, 
Nabata et al., 1989, Puthier et al., 1999). IL-6 function can also be triggered using the  
“trans-signaling” pathway which is activated by binding soluble IL-6R (Mülberg et al., 
1993, Jones and Rose-John, 2002). Through this pathway, IL-6 can function in the 
absence of membrane-bound IL-6R. In the future, characterization of the ChIL-6 
pathway will help us to further understand the mechanism of ChIL-6 regulation. 
Currently, our knowledge of chicken immunology is limited. In this present study, we 
have found that ChIL-6 showed similar characteristics to mammalian IL-6, including 
regulation of cell proliferation, apoptosis and antiviral activity. Given time constraints 
associated with PhD candidature, virus titer and cytokine expression in ChIL-6-/- cells 
was only tested at one time-point (24h post infection). In the future, multiple time-points 
will be investigated to provide additional knowledge. The role of ChIL-6 in immune cell 
migration will require the production of a ChIL-6-/- chicken. In the following chapter, we 
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applied CRISPR/Cas9 technology to generate ChIL-6-/- PGCs to pave the way forward 
for the future generation of ChIL-6-/+ or ChIL-6-/- chickens.  
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Chapter 5   Generation of IL-6-knockout chicken   
primordial germ cells 
 
5.1 Introduction 
The first transgenic chicken was generated in 1987 using an avian retrovirus vector 
derived from avian leucosis virus (Salter et al., 1987). Since then, retrovirus vectors 
have been widely used to modify chicken genomic DNA (Bosselman et al., 1989a, 
Bosselman et al., 1989b, Bosselman et al., 1989c, Harvey et al., 2002a). However, 
the efficiency of gene modification using avian retrovirus vectors is approximately 0.5% 
in first generation progeny (Doran et al., 2016). Lentiviral systems were subsequently 
developed as gene delivery vectors to improve efficiency. The frequency of stable 
transmission using lentiviral vectors is between 4% and 45% in roosters (Mcgrew et 
al., 2004). Unfortunately, integration of viral genes into the host genome occurs 
randomly and a viral DNA footprint is left in the chicken genome. To avoid the potential 
risk of lentiviral insertion, inducing oncogenesis, non-viral vectors such as piggyBac 
and Tol2 transposons were developed to generate transgenic chickens (Macdonald 
and Mcgrew, 2012). Alternatively established long-term in vitro culture of chicken 
primordial germ cells (PGCs) offers an additional pathway to generate transgenic 
chickens . PGCs are precursor germ cells that are derived from various embryonic 
stages and show high transmission efficiency when injected into the bloodstream of 
recipient embryos (Naito et al., 1994, Tajima et al., 1998, Macdonald et al., 2012). The 
efficiency of piggyBac and Tol2 vectors to generate stable transfection of genes of 
interest in chicken PGCs is reported to be between 10.5% and 42.5% (Macdonald et 
al., 2012). It should be noted however, that all of the abovementioned vectors insert 
foreign genes of interest randomly into the chicken genome. As such, these 
technologies do not give us the ability to generate precise, genetically modified 
chickens or other avian species for biological research studies. 
The generation of precisely, genetically modified avian species has lagged far behind 
mammalian species due to the lack of a one-cell-stage in the egg. As such, many 
gene-editing technologies that are suitable for mammalian species are not applicable 
for avian species. The first targeted gene knockout chicken with a precise disruption 
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of the immunoglobulin heavy chain gene was generated in 2013 using homologous 
recombination with the efficiency of 1 in 107 transfected PGCs (Schusser et al., 2013). 
The low gene modification efficiency of this method failed to significantly advance the 
generation of genetically modified chickens.  
Previous studies have showed that the presence of double-strand breaks can increase 
the chance of homologous recombination (Rothkamm et al., 2003, Lieber, 2010). 
Therefore, site-specific endonucleases that can produce a double-strand break have 
been employed in the precise genome-editing field. The first widely used tool in this 
field were Zinc Finger Nucleases (ZFN). These nucleases contains a tandem array of 
Crys-His2 figures, with each figure recognizing 3 nucleotides as shown in Figure 1.3 
(Kim et al., 1996). A pair of three figures can therefore be designed to target a number 
of genetically modified animals, such as mice (Carbery et al., 2010), pigs (Hauschild 
et al., 2011) and cattle (Shengli Yu, 2011). The only reported application of ZFNs in 
chickens was to target the ovalbumin gene in vitro (Fan et al., 2011). In 2010, an 
improved nuclease-based genome editing tool was developed, termed transcription 
activator-like effector nucleases (TALENs). TALENs are composed of a range of a 
TAL effector DNA-binding domains with each domain having the ability to recognize 
one nucleotide as shown in Figure 1.4 (Boch et al., 2009). TALEN technology was 
used to generate a ovalbumin (OV) gene-knockout chicken (Park et al., 2014). In this 
study, the TALEN construct was designed to target exon 2 of the OV gene in chicken 
PGCs and the modified PGCs were then transplanted into a recipient embryo. An 8.0% 
average mutation rate was achieved in the chicken progenies (Park et al., 2014).  
Most recently, a bacterial derived CRISPR system was engineered to edit eukaryotic 
genomic DNA (Alibrandi, 2013). In Chapter 3, we validated the gene modification 
efficiency of the CRISPR/Cas9 plasmid in two chicken cell lines, DF1 and HD11 cells.  
The next step in this process is to generate IL-6-knockout chicken PGCs to assist with 
the future generation of IL-6-knockout chicken. Chicken PGCs are primary stem cells 
that require complex culture conditions and have low transfection efficiency 
(Chojnacka-Puchta et al., 2012). We report the establishment of a simple and efficient 
enrichment protocol to modify the ChIL-6 gene in PGCs.   
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5.2 Results 
5.2.1 Genomic modification of chicken PGCs using Lipofectamine-mediated 
transfection of CRISPR/Cas9 constructs  
As described in the protocol outlined in Chapter 3, primary chicken PGCs were 
transfected with 1 µg guide RNA (gRNA), 1 µg Cas9 plasmid and 1 µg liner homology 
directed repair (HDR) template. However, only less than 0.1% of PGCs were GFP-
positive cells at 24 h post-transfection when analyzed by fluorescence activated cell 
sorting (FACS) (Figure 5.1B). The transfection efficiency was much lower than 
previous DF1 and HD11 transfections (Figure 3.1A). In our troubleshooting, we 
suspected the linear HDR template may contribute to the low transfection efficiency 
as it could be degraded soon after transfection (Carroll and Beumer, 2014). The liner 
HDR template was then inserted into a pGEM-T vector and turned into a circular HDR 
template, that in turn increased the transfection efficiency from less than 0.1% to 27.4% 
(Figure 5.1). However, after two-weeks of culture, we did not observe GFP-positive 
cells in transfected PGCs (data not shown). In previous studies, the length of the HDR 
template used to insert large sequences has been shown to be at least 1kb (Dickinson 
et al., 2013, Yang et al., 2013, Wang et al., 2015a). As such, the length of the 
homologous arms in our study were increased from ~100 bp to ~1 Kb (left arm 
increased from 121bp to 1254bp; right arm increased from 100bp to 953bp) (Figure 
5.2). However, we failed to generate GFP-positive PGCs using the above-mentioned 
method (data not shown). 
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Figure 5.1. Increased transfection efficiency using circular HDR templates. Chicken PGCs were 
transfected with 1 µg gRNA, 1 µg Cas9 plasmid and 1 µg linear HDR template. After 24 h, the 
transfected PGCs were observed under bright light field (A) and fluorescent light field (B) at 100x 
magnification. Less than 0.1% of GFP-positive cells were observed in transfected PGCS. The PGCs 
were then transfected with 1 µg gRNA, 1µg Cas9 plasmid and 1µg circular HDR template and observed 
under bright light field (C) and fluorescent light field microscope (D) 24 h post-transfection. The 
percentage of GPF-positive cells in transfected PGCs was 27.3%.  
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Figure 5.2. Construction of a 3.7Kb HDR template.  (A) Schematic of a 3.7kb designed HDR template. 
Two new pairs of primers (HR-3.7kb-UF&HR-3.7kb-UR and HR-3.7kb-DF&HR-3.7kb-DR, listed in Table 
2.2) were designed to extend the homologous arms used in Chapter 3 (Figure 3.2) from ~100 bp to 
~1000 bp in length. (B) PCR product of the 3.7 kb-HDR template. Lane 1, a 3.7 Kb- PCR product 
amplified from the pEMG-T vector containing a 3.7 Kb-HDR template. Lane 2, a negative control 
amplified using an empty pGEM-T vector as a template.  
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5.2.2 Genomic modification of chicken embryotic PGCs via direct injection of 
CRISPR/Cas9 constructs into chicken embryos 
Previous studies have demonstrated that circulating PGCs in chicken embryotic blood 
vessels can be modified by directly injecting Tol2 plasmids into the embryo; termed 
the direct injection method (Tyack et al., 2013). We were curious to see if the 
CRISPR/Cas9 system could modify embryotic PGCs via this direct injection method 
to avoid culturing PGCs in vitro. We had two types of gRNA-expression backbone 
vectors (Figure 5.3). The first was the gRNA_Cloning Vector (Addgene #41824) used 
in Chapter 3 that was generated in the Church lab (Mali et al., 2013b). The second 
was the pSpCas9(BB)-2A-Puro vector (Addgene #48139) that was generated in the 
Zhang lab(Ran et al., 2013b). The pSpCas9(BB)-2A-Puro plasmid integrates gRNA-
expression and Cas9-expression together along with the puromycin-resistance gene 
for screening of transfected cells. We inserted the same target sequencing (Target 1 
shown in Figure 3.1) into the pSpCas9(BB)-2A-Puro plasmids, and named it IL-6-
gRNA-Cas9-1. We chose one of the two gRNA-expressing vectors (IL-6-gRNA-1 and 
IL-6-gRNA-Cas9-1) and one of two different–length HDR templates (1.8kb HDR 
template and 3.7kb HDR template) respectively to set a 4-group experiment outlined 
in Table 5.1.  These CRISPR/Cas9 plasmids and HDR template were directly injected 
into chicken embryotic blood vessels. Seven days after injection, the gonads were 
dissected from chicken embryos and examined under a fluorescent microscope. We 
failed to observe GFP insertion in isolated chick embryo gonads from the different 
groups (Table 5.1).  These results indicated it was not practical to use the direct 
injection method to insert GFP into the ChIL-6 gene in circulating PGCs. 
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Figure 5.3. Schematic of gRNA expression vectors. (A) The gRNA_Cloning Vector expresses 
functional gRNA under a U6 promoter. (B) The pSpCas9(BB)-2A-Puro vector expresses gRNA under a 
U6 promoter and Cas9 that is fused with puromycin under a CMV promoter. 
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Table 5.1. Direct injection of chicken PGCs 
Experimental   
group 
Plasmids used for 
direct injection 
The number 
of injected 
chicken 
embryos 
The number of 
alive chicken 
embryos at day 
7 post-injection 
GFP signal 
observed under 
fluorescent 
microscope 
GFP insertion 
detected by 
PCR 
A IL-6-gRNA-1 
hCas9 
1.8kb HDR template 
10 5 None Negative 
B IL-6-gRNA-1 
hCas9 
4.0kb HDR template 
10 7 None Negative 
C IL-6-gRNA-Cas9-1 
Homologous Arms-
1.8kb 
10 9 None Negative 
D IL-6-gRNA-Cas9-
EGFP (target 2) 
Homologous Arms-
4.0K 
10 5 None Negative 
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5.2.3 Co-targeting strategy established to simultaneously target the ChIL-6 gene 
and the GFP gene in GFP-positive DF1 cells 
We found low efficiency of transfection and modification of PGCs when compared with 
results in DF1 and HD11 cells Chapter 3 Figure 3.3 (Figure 5.1), especially when we 
tried to insert a large GFP-expressing cassette into the chicken genome (Song and 
Stieger, 2017). In light of the reported multiple-cutting feature of the CRISPR/Cas9 
system (multiple genes can be modified by transfecting various gRNAs) (Cong et al., 
2013), we developed a co-targeting strategy to simultaneously target the ChIL-6 and 
GFP genes. The GFP-positive DF1 cell line and the GFP-positive PGCs used in this 
chapter were kind gifts from Dr. Timothy Doran (CSIRO AAHL) which  were generated 
using the published Tol2 construction method (Tyack et al., 2013). 
With the availability of an online gRNA design tool (http://crispr.mit.edu/), two new 
CRISPR/Cas9 gRNAs (named target 2 and 3) were designed to target sites in exon3 
of the ChIL-6 gene (Figure 5.4A). These two gRNAs had high prediction scores, 
suggesting high gene-modification efficiency and low off-target effects (97 for target 2 
and 93 for target 3) which is higher than our previously designed target in exon2 (86 
for target 1), Following the protocol established in the Zhang lab, target 2 and target 3 
sequences were inserted into pSpCas9(BB)-2A-Puro plasmids and novel 
CRISPR/Cas9 constructs were named IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3 
respectively (Figure 5.4B).  The simultaneous transfection of these two plasmids 
would theoretically mediate the deletion of approximate 140bp nucleotides in ChIL-6 
exon 3, resulting in a large deletion of exon 3 (Figure 5.4A). The GFP-gRNA plasmid 
used in this chapter was previously generated by the Church lab whose backbone is 
a gRNA_Cloning Vector (Figure 5.4B). The GFP-gRNA can only express gRNA to 
target GFP gene and its function is dependent on the Cas9 protein expressed from 
the IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3 constructs. The presence of IL-6-
gRNA-Cas9-2 or IL-6-gRNA-Cas9-3 is necessary to turn a GFP-positive cell into GFP-
negative. This allows modified ChIL-6 cells to be enriched by sorting on GFP-negative 
cells. The gene-modification efficiency of the IL-6-gRNA-Cas9-2 and IL-6-gRNA-
Cas9-3 constructs was first assessed in GFP-positive DF1 cells to determine is this 
modified protocol was feasible. GFP-positive DF1 cells were transfected with the 
mixture of IL-6-gRNA-Cas9-2, IL-6-gRNA-Cas9-3 and GFP-gRNA plasmids (at a ratio 
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of 1:1:1). After being cultured for 2 weeks, GFP-negative DF1 cells were sorted by 
FACS. ChIL-6 gene mutations of sorted cells were analyzed by PCR (using primers 
IL-6-3F&IL-6-3R in Table 2.2). A 549bp band (the expected PCR product from a WT 
ChIL-6 gene) was amplified from genomic DNA extracted from GFP-positive DF1 cells 
(Figure 5.4C). Three bands of different size (549bp, ~500bp, ~420bp); the change in 
sequence length caused by CRISPR/Cas9 cannot be predicted in an exact number. 
The ~420bp band was our expected PCR product amplified from the ChIL-6 gene 
targeted by our two gRNAs (target2 and target3). We purified the ~420bp fragments 
and inserted them into the pGEM-T vector individually. After transformation three 
bacterial clones were picked for sequencing. Sequencing showed that two clones had 
a 144-nuclotide deletion and one clone has a 163-nucleotide deletion between the two 
target sites. We characterized the unexpected ~500bp band in the next section. 
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Figure 5.4. Enrichment of modified DF1 cells using a newly designed CRISPR/Cas9 plasmids. 
(A) Schematic of the IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3 constructs, targeting two sites in exon 
3 of the ChIL-6 gene. (B) Schematic of three CRISPR/Cas9 constructs, IL-6-gRNA-Cas9-2, IL-6-gRNA-
Cas9-3 and GFP-gRNA used in our co-targeting strategy. (C) PCR amplification of genomic DNA 
extracted from enriched and FACS-sorted GFP-negative DF1 cells. Lane 1: enriched GFP-negative 
DF1 cells following transfection of IL-6-gRNA-Cas9-2, IL-6-gRNA-Cas9-3 and GFP-gRNA; Lane 2: 
GFP-positive DF1 cells. (D) Sequencing results of the ~420bp band (Lane1 in Figure 5.4C) in a pGEM-
T vector.  
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5.2.4 Characterization of the unexpected ~500bp band 
In section 5.2.3, we identified an ~500bp band. This section analyzes whether this 
band is caused by off-target effects associated with the design of gRNAs. The ~500bp 
PCR fragment was purified and inserted into a pGEM-T vector. After transformation 
seven bacterial clones were picked and analyzed by PCR using primers (IL-6-3F&IL-
6-3R listed in Table 2.2). The PCR results showed 4 of the 7 clones had a 549bp 
insertion, 2 of them had a ~420bp fragment and 1 of them showed three PCR bands 
(as in Figure 5.4C) (Figure 5.5). We speculated that the ~500bp band was a hybrid of 
the 549bp and ~420bp bands. To test this hypothesis, the purified 549bp and ~420bp 
PCR fragments were mixed together at a ratio of 1:1 and heated at 100℃ for 5min to 
denature the bands. Then the mixture was cooled to room temperature to allow 
annealing and analyzed on a DNA gel. As shown in Figure 5.5B, a DNA band of 
~500bp correlated to the ~500bp band in Lane 1, Figure 5.4C.  
To further confirm whether the ~500bp band was a mismatch between the 549bp and 
~420bp bands, a surveyor nuclease assay which can cleave mismatched bands was 
performed. The results show that the ~500bp band can be removed after surveyor 
nuclease treatment (Figure 5.5C). Here, we confirm the unexpected band was derived 
from a mismatch between the 549bp and ~420bp bands and is not associated with 
off-target effects associated with the design of gRNAs. We applied this co-targeting 
strategy to GFP-positive PGCs in the following section. 
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Figure 5.5. Characterization of the unexpected ~500bp band. The ~500bp band from Lane 1 in 
Figure 5.4C was purified and then inserted into pGEM-T vector individually. (A) Seven bacterial clones 
(Lane1 to Lane7) were picked and analyzed by PCR using IL-6-3F&IL-6-3R primers (B) A ~500bp band 
can be produced by annealing a 549bp and a ~420bp band. Lane 1, the purified 549bp band; Lane 2, 
the purified ~420bp band; Lane 3, an additional DNA band corresponding to the ~500bp band is visible 
after mixing and annealing. (C) The hybrid ~500bp band was cleaved using a surveyor nuclease assay. 
Lanes 1-3 correspond to the same samples as in Figure 5.5B. The ~500bp band was not observed in 
Lane 4 following use of the Surveyor nuclease assay.  
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5.2.5 Generation of ChIL-6-/- PGCs 
The co-targeting strategy (as documented in section 5.2.2) was used to transfect GFP-
positive chicken PGCs. After culturing for 2 weeks, GFP-negative PGCs were 
observed, indicating alterations in the GFP gene caused by the action of 
CRISPR/Cas9 (Figure 5.6A). Flow cytometric analysis of GFP-positive PGCs 
transfected with GFP-gRNA, IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3 showed only 
2.24% of the transfected cells were GFP-negative, indicating a very low modification 
efficiency (Figure 5.6B). To enrich GFP-negative PGCs, transfected cells were sorted 
by FACS. After enrichment, 94.6% of PGCs were GFP-negative, indicating successful 
enrichment (Figure 5.6B). IL-6-3F&IL-6-3R primers were used to amplify the ChIL-6 
target 2 and 3 regions to confirm deletion/modification. Similar to the results in the 
previous section (Section 5.2.2), the PCR products from transfected PGCs showed 
three bands (549bp, ~500bp and -420bp) (Figure 5.7A). Only one 549bp band was 
amplified from control PGCs without transfection (Figure 5.7A).   
The enrichment efficiency was further analyzed through analysis of PCR products. 
DNA gel analysis of PCR products showed ~ 65.0% of the ChIL-6 gene was deleted 
by two CRISPR/Cas9 gRNAs after enrichment based on the intensity of the ~420bp 
band, while there was only 0.09% of the modified ChIL-6 gene in non-enriched cells 
(Figure 5.7A). The PCR product with ~420bp was then purified and inserted into a 
pGEM-T vector for sequencing. After transformation, six bacterial clones were picked 
and five of them contained a 141-nucleotide deletion and one of them had a 147-
nucleotide deletion between two target sites (Figure 5.7B). In conclusion, ChIL-6 
modified PGCs can be effectively enriched using this co-targeting method.  
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Figure 5.6. Efficient enrichment of GFP-negative chicken PGCs. (A) Visualization of GFP-negative 
chicken PGCs before (left) and after (right) FACS enrichment using fluorescence microscopy at 200x 
magnification. (B) FACS analysis of PGC populations; (1) Untransfected GFP-positive PGCs; (2) GFP-
positive PGCs transfected with GFP-gRNA, IL-6-gRNA-Cas9-2 and IL-6-gRNA-Cas9-3 CRISP/Cas9 
constructs; (3) Enriched GFP-negative PGCs by FACS.  
		
	
104	
 
Figure 5.7. Modification of the ChIL-6 gene in GFP-negative PGCs. (A) PCR amplification of 
genomic DNA extracted from (1) non-enriched PGCs transfected with IL-6 gRNAs and GFP-gRNA, (2) 
enriched GFP-negative PGCs transfected with IL-6 gRNAs and GFP-gRNA, (3) non-transfected GFP-
positive PGCs. (B) Sequencing of the ~420bp band (Lane 2 in Figure 5.7A) ligated into a pGEM-T 
vector. The PAM sequences for designed IL-6 gRNAs are shown in red. 
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5.2.6 Migration of IL-6-knockout chicken PGCs to gonads 
In-vitro cultured chicken PGCs have been found to be able to migrate into gonads 
when reinjected into the recipient chicken embryos (Kim et al., 2010). Firstly, to ensure 
that GFP-positive PGCs used in this study had the same migration ability as 
unmodified chicken PGCs, more than 5000 GFP-positive PGCs were injected into the 
dorsal aorta of seven chicken embryos. The gonads from these chicken embryos were 
removed 7 days after injection and observed under a microscope. As shown in Figure 
5.8, GFP-positive chicken PGCs can migrate to gonads normally. Enriched GFP-
negative chicken PGCs encoding the ChIL-6 modification were then injected into 17 
chicken embryos to test migration. At 7 days after injection, gonads from the 17 
chicken embryos were collected, pooled and digested with 0.25% trypsin for 7 min at 
37°C. A magnetic-activated cell sorting (MACS) purification column conjugated with 
chicken stage specific embryonic antigen 1 (SSEA-1) antibody was used to sort PGCs 
from digested gonads. A total of approximately 25000 PGCs were sorted from pooled 
chicken embryonic gonads. Genomic DNA was prepared from these cells and used 
as a template to amplify the ChIL-6 gene with the IL-6-3F and IL-6-3R PCR primer 
pair. Our results from DNA gel analysis showed 15.6% of sorted embryotic PGCs had 
a mutated ChIL-6 gene (Figure 5.9A). Purified ~420bp fragments were inserted into 
the pGEM-T vector and after transformation, 3 bacterial clones were picked for 
sequencing. The sequencing results showed a 141-nucleotide deletion in all clones, 
the same deletion as that observed with injected PGCs (Figure 5.9B). From these 
results, we concluded that modified ChIL-6-/- PGCs can migrate to gonads. 
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Figure 5.8. Migration of GFP-positive chicken PGCs to gonads. GFP-positive chicken PGCs were 
injected into the dorsal aorta of 2.5-day old chicken embryos. Gonads were removed 7 days after 
injection and observed under a green florescent field (A) or under a bright light field (B) at 100x 
magnification. 
 
 
 
 
 
 
 
 
 
		
	
107	
 
Figure 5.9. Migration of ChIL6-modified PGCs to gonads in chicken embryos. (A) PCR 
amplification of genomic DNA extracted from (1) gonad PGCs from a 7-day old chicken embryo recipient, 
(2) enriched GFP-negative PGCs used for injection, (3) non-injected chicken gonad PGC controls. (B) 
Sequencing of the ~420bp band (Lane 1 in Figure 5.9A). The PAM sequences for designed IL-6 gRNAs 
are shown in red. 
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5.3 Discussion 
Outbreaks of influenza virus are a huge risk for the poultry industry resulting in 
enormous economic losses. In a recent outbreak of HP AIV in the USA in 2015 an 
estimated $3.3 billion of economic losses were incurred (Greene, 2015). In addition, 
these viruses are an ongoing threat to human health as chickens act as a reservoir for 
transmission of virus as observed with the H7N9 outbreak in China (Chen et al., 2013a, 
Husain, 2014, Tang et al., 2017).  As such a large scientific effort has been put in place 
to develop genetically modified chickens that are resistant to infection (Zhang et al., 
2010b). In 2011, a transgenic chicken resistant to influenza virus transmission was 
generated. It was generated through the insertion of a decoy RNA targeting the 
influenza virus polymerase into the chicken genome (Lyall and Tiley, 2011). 
Unfortunately, these chickens were still susceptible to the high pathogenicity influenza 
virus infection (Lyall and Tiley, 2011). Currently, very little is known about the host-
pathogen interactions between chickens and influenza viruses.  Highly elevated IL-6 
expression following avian influenza virus infection in humans and chickens is thought 
to be associated with morbidity and mortality (Beigel et al., 2005, Burggraaf et al., 
2014). The generation of heterozygous and homozygous IL-6-knockout chickens has 
the ability to provide an ideal animal model to characterize the role of ChIL-6 in 
pathogenicity of disease in its natural host. To date, modifying genes in cultured PGCs 
in vitro has been the most feasible approach for generating knockout chickens. In this 
chapter, we established a simple and effective method to enrich ChIL-6 modified 
PGCs by targeting GFP and ChIL-6 gene simultaneously in GFP-positive PGCs. 
Multiplex genome engineering is a characteristic of the CRISPR/Cas9 system that has 
advantages over TALENs and ZFNs because of its use of gRNA (a 20bp sequence 
with a tracRNA scaffold). Multiple gRNAs sharing a common Cas9 protein can be 
transfected into a cell to modify targets. To date, the CRISPR/Cas9 has been shown 
to modify up to seven genes simultaneously (Sakuma et al., 2014). Multiple genome 
engineering has also been employed to facilitate enrichment of modified cells. 
Hypoxanthine phosphoribosyltransferase (HPRT) is a catalyzing enzyme that 
regulates the conversion of hypoxanthine to inosinemonophosphate and guanine to 
guanosine monophosphate. The cells with destructive HPRT can be screened by 
resistance to 6-thioguanine (6-TG) (Liao et al., 2015b). Co-targeting the HPRT gene 
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and a gene of interest in human HCT116 cells has been used to enrich the modified 
cells under 6-TG selection (Liao et al., 2015b).  
Low gene modification efficiency in chicken PGCs was observed in our study when 
we tried to insert GFP into the ChIL-6 gene using CRISPR/Cas9. Given the multiplex 
genome engineering capacity of CRISPR/Cas9, we tried to develop a novel strategy 
to avoid integration of large sequences as well as maintain a selective marker. 
Therefore, GFP-positive PGCs were chosen for modification (established by several 
groups using Tol2 or piggyBac transposon) (Macdonald et al., 2012, Park and Han, 
2012, Tyack et al., 2013). As the results showed in section 5.2.4, ChIL-6-modified 
PGCs were enriched efficiently through sorting of GFP-negative cells. In addition to 
enrichment, this strategy can be used to validate the targeting efficiency of designed 
gRNAs. Due to the complexity of genome structure, especially for stem cells like PGCs, 
the targeting efficiency of a gRNA varies considerably, which cannot be predicted by 
online software. In theory, the targeting efficiency of GFP-gRNA is relatively consistent. 
Therefore, when using a co-targeting strategy, the designed gRNA targeting efficiency 
can be estimated through comparing the mutation rate in GFP-negative cells. This co-
targeting strategy can also indicate if the targeted gene is lethal for the cells when a 
very low percentage of GFP-negative cells is observed.  
In 2016, two groups reported the successful generation of knockout chickens using 
CRISPR/Cas9 technology. The first group targeted the ovalbumin and ovomucoid 
genes in chicken PGCs. Heterozygous and homozygous knockout chicks were 
generated by transplanting modified PGCs into recipient embryos (Oishi et al., 2016). 
The second study used the CRISPR/Cas9 system to cleave the immunoglobulin heavy 
chain gene in chicken PGCs and heterozygous knockout chickens were generated by 
re-introducing these modified PGCs back into chicken embryos (Dimitrov et al., 2016). 
In a similar fashion to our study, modified PGCs were enriched in vitro through drug 
selection before they were injected into recipient chicken embryos. Enrichment 
efficiencies varied in different studies  with >90% in ovomucoid-mutated chicken PGCs 
(Oishi et al., 2016) and 20%~75% in the immunoglobulin heavy chain-mutated chicken 
PGCs (Dimitrov et al., 2016). This was compared to our ~65% (Figure 5.7). 
Enrichment is a vital step in order to increase the number of genetically modified chicks 
in subsequent selection. In our study, drug selection was not considered owing to the 
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lack of drug-resistant feeder cells for chicken PGC culture. However, these published 
studies showed drug-resistant feeder cells are not necessary for PGC enrichment 
(Oishi et al., 2016, Dimitrov et al., 2016). Our constructs expressing gRNAs also 
contain a puromycin-resistant gene (Figure 5.3). Future studies will compare 
enrichment efficiency using a co-targeting strategy with puromycin selection. 
Currently, generation of transgenic chickens is still labor-intensive and time-
consuming. Insertion of a selection marker such as GFP, is widely used in the 
generation of transgenic chickens to allow efficient screening of chicks (Schusser et 
al., 2013, Tyack et al., 2013, Dimitrov et al., 2016). In studies without a GFP maker, 
feather color selection has been applied for screening (Park et al., 2014, Oishi et al., 
2016).  In this chapter, the aim of targeting GFP-gene was to facilitate following 
enrichment.  
A main drawback of our co-targeting strategy is that the GFP-positive PGCs have 
been generated using a Tol2 system where the GFP gene was inserted randomly into 
the chicken genome (Tyack et al., 2013). In our study, we found it was difficult to 
integrate the GFP into the ChIL-6 gene (see 5.2.1). However, Dimitrov et al., have 
integrated GFP into the immunoglobulin heavy chain gene successfully (Dimitrov et 
al., 2016). This indicates that the integration efficiency of GFP into the chicken genome 
is a site-dependent event. For wider application in the future, it would be appropriate 
to generate GFP-positive PGCs that maintain a GFP gene in a non-coding site using 
CRISPR/Cas9 system.  
In conclusion, the generation of an IL-6 knockout chicken is still in its infancy and 
numerous optimization experiments are required to accelerate this process.  
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Chapter 6   General Discussion 
 
6.1 Overall discussion 
As an important livestock animal, the chicken provides the largest source of protein 
for human consumption. In addition, chicken eggs are used in significant numbers to 
produce influenza vaccine (Matthews, 2006). However, there are significant issues 
that need to be solved in the poultry industry that revolve around enhancing anti-viral 
traits of chickens, increasing egg and meat production and sex determination to avoid 
the killing of day-old male chicks (Doran et al., 2016). The most feasible path forward 
is to modify appropriate genes in the chicken genome. However, the technology 
involving manipulation of chicken genes lags far behind that optimized for mammalian 
species due mainly to the unique characteristics of chicken embryotic development. 
The isolation and reinjection of a chicken zygote is not practical. Given this, powerful 
genome editing tools are required to modify the chicken genome. When CRISPR/Cas9 
technology was first reported in 2012 (Jinek et al., 2012), our research team was one 
of the first to apply this technology in chickens. In this thesis, we describe the mutation 
of the ChIL-6 gene using the CRSIRP/Cas9 system in chicken DF1 and HD11 cell 
lines and in PGCs. Furthermore, a protective role for ChIL-6 was established when we 
infected ChIL-6-/- -DF1 and -HD11 cells with influenza virus. 
Recently, manipulation of chicken genes using the CRISPR/Cas9 system has been 
reported by several groups. Oishi et al., reported that knockout chickens generated 
through the use of a CRISPR/Cas9 system targeted two egg white genes; ovalbumin 
(OVA) and ovomucoid (OVM) (Oishi et al., 2016). These OVA- or OVM- knockout 
chickens are being developed to produce hypo-allergenic eggs (Oishi et al., 2016). 
Heterozygous immunoglobulin heavy chain (IgH)-knockout chickens have also been 
generated using the CRISPR/Cas9 system with the potential for use in the production 
of humanized antibodies (Dimitrov et al., 2016).  Similar to the work described in this 
thesis, other published studies have validated the use of the CRISPR/Cas9 system in 
chicken cell lines. Mutation of the chicken myostatin gene (a gene involved in the 
regulation of meat production) was validated in DF1 cells (Wang et al., 2017, Lee et 
		
	
112	
al., 2017). Genes involved in microRNA processing, such as Dicer and Drosha, have 
also been targeted in DF1 cells (Abu-Bonsrah et al., 2016). These studies, as well as 
our own work demonstrate that the CRISPR/Cas9 system can efficiently target the 
chicken genome. 
The CRISPR/Cas9 system has been continuously optimized over the past three years. 
For example, a mutant Cas9 variant, Cas9-10A nickase, has been generated to 
reduce off-target effects because it has the capacity to break only one DNA strand 
compared to two strands associated with WT Cas9 function (Ran et al., 2013a, Shen 
et al., 2014). As such, only paired nickases binding opposite DNA strands will produce 
a double stranded break. Single nicking would be repaired with high fidelity through 
the base excision repair pathway (Ran et al., 2013a). Recently, Cas9-10A has been 
shown to cleave chicken genes without off-target effects (Lee et al., 2016).  
Ahn et al, further optimized the application of CRISPR/Cas9 system to avian species 
by replacing the guide RNA promoter with avian-specific promoters (Ahn et al., 2016). 
In our studies presented herein, we also modified our constructs (gRNA Cloning 
Vector used in chapter 3 vs pSpCas9(BB)-2A-Puro vector used in Chapter 5) and 
targets (Target 1 used in chapter 3 (Figure 3.1) vs Target 2&3 used in chapter 5 (Figure 
5.4)) to improve the CRISPR/Cas9 system. In the future, other novel improvements to 
the CRISPR/Cas9 system should be further assessed in chickens. For example, our 
failure to integrate GFP into the ChIL-6 gene indicated the dominance of non-
homologous ending jointing (NHEJ) repair over homologous recombinant (HR) repair 
in chicken primordial germ cells (PGCs). Similarly, NHEJ is a dominant pathway over 
HR in mammalian cells. Previous studies have showed that co-transfection of a ligase 
inhibitor (SCR7) into various mammalian cells can increase the efficiency of HR repair 
by up to 19 fold (Maruyama et al., 2015).  HR repair efficiency in HEK293 and iPSC 
cell lines was recently improved using an optimized CRISPR/Cas9 system and 
homology directed repair (HDR) template ie. phosphorothioate protection of HDR 
template alongside optimised electroporation conditions (Liang et al., 2016). 
Strategies that increase the frequency of HR in genome repair processes could be 
further applied in chicken genome editing. 
The techniques developed in this PhD project to manipulate the chicken genome will 
help dissect and better characterize the chicken immune system. For the most part, 
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the chicken immune system functions in a similar manner to the mammalian immune 
system involving both the innate and adaptive arms. Importantly, chicken immune 
genes share ~25%-35% amino acid identity with their mammalian counterparts 
(Davison et al., 2011) so use of mammalian reagents or antibodies is limited. 
Consequently, there are very few studies that illustrate the complexity of the chicken 
immune system. We used CRISPR-modified DF1 and HD11 cell lines to illustrate the 
protective role of ChIL-6 in anti-influenza responses in vitro. Similar to mammalian IL-
6, ChIL-6 also plays a role in regulating cellular proliferation and apoptosis in a cell-
dependent manner. Moreover, aberrant expression of cytokines (LITAF, IFN-β, IL-10 
and Mx) was observed in ChIL-6-/- cells post influenza infection. Using a similar 
strategy, the role of other highly expressed cytokines such as IFN-g, IL-1b, IL-10 and 
CXCL10 (Burggraaf et al., 2014, Kuchipudi et al., 2014), could be further investigated 
in numerous influenza virus models 
A better understanding of chicken immune responses following influenza virus 
infection will accelerate the generation of an influenza resistant chicken. As mentioned 
in earlier chapters, avian influenza infection causes huge economic losses for the 
poultry industry and is a potential risk to human health. Three strategies have been 
previously used to enhance chicken anti-viral traits: 1) targeting vital genes known to 
contribute to high pathogenicity 2) introduction of anti-viral genes into the chicken 
genome and 3) insertion of decoy genes into the chicken genome that target influenza 
viruses. Perhaps a combination of deletions will improve survival as has been shown 
with triple-knockout mice (TNF-receptor1-/-, TNF-receptor2-/- and IL-1receptor-/-) 
following H5N1 infection (Perrone et al., 2010). Taking advantage of the multiple-
cutting feature of the CRISPR/Cas9 system, multiple genes could be manipulated in 
chicken cells in one transfection reaction. Previous studies have also compared 
responses to influenza infection between chickens and ducks highlighting the key role 
for retinoic-acid-inducible protein I (RIG-I), a vital influenza virus sensor  (Barber et al., 
2010, Smith et al., 2015). Transfection of duck RIG-I into chicken DF1 cells has been 
shown to inhibit influenza virus replication (Barber et al., 2010). Integration of the duck 
RIG-I into chicken genome using a CRISP/Cas9 system may therefore enhance 
chicken anti-influenza responses. Lastly, an influenza virus decoy  (a short RNA 
hairpin) that targets viral polymerase, has been inserted into the chicken genome 
using a lentiviral vector to suppress viral transmission between chickens (Lyall and 
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Tiley, 2011). The CRISPR/Cas9 system will allow the insertion of RNA interference 
molecules, such as short RNA hairpins) into the chicken genome more precisely.  
The transposons, Tol2 and piggyBac, have been widely used to insert RNA 
interference molecules into the chicken genome to silence genes (Sato et al., 2007, 
Lu et al., 2009). The first published paper applying CRISPR technology in chickens 
used a combination of the Tol2 and CRISPR systems together. Véron et al., used the 
Tol2 system to insert a CRISPR expressing cassette targeting PAX7 (a transcription 
factor) into the chicken genome (Véron et al., 2015). In our study (chapter 5), we have 
also combined the Tol2 and CRIPSR systems. GFP-positive PGCs generated using a 
Tol2 system were used as CRISPR targets.  
Manipulation of the chicken genome will also expand the use of chickens as an animal 
model. Chicken embryos could be used to understand embryology and or cancer 
biology (Dodgson and Romanov, 2004). Improvements of in ovo transfection protocols, 
embryo ex-ovo culture and live imaging have facilitated the use of chicken embryo as 
model systems (Mok et al., 2015). Combining these advanced technologies would 
make the chicken model robust so it could be applied to human disease prevention. 
6.2 Conclusions  
This project has successfully used CRISPR/Cas9 genome-editing technology to 
analyze the chicken immune response to influenza virus infection. The major 
outcomes of this project include: 
1): Validation of humanized CRISPR/Cas9 plasmids in chicken DF1 and HD11 
cells.  
 
2): Illustration of the role of ChIL-6 in anti-influenza immunity in chicken cell lines. 
 
3): Establishment of a co-targeting method to enrich ChIL-6-/- PGCs 
6.3 Future directions	
ChIL-6-/- PGCs have the ability to migrate to gonads. Therefore, it will be feasible to 
directly inject ChIL-6-/--PGCs into chicken embryos for the generation of heterozygous 
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and homozygous chicks. The generation of ChIL-6-/- chickens will allow a detailed 
dissection of anti-influenza immunity.  
In addition to influenza virus, ChIL-6 expression is also associated with susceptibility 
of chickens to Marek’s disease virus (MDV) and infectious bursal disease virus (IBDV) 
(Kaiser et al., 2003, Fernando et al., 2015). The ChIL-6-/- chicken will provide an ideal 
model to illustrate the role of ChIL-6 in these infectious diseases. 
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